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Introduction 
The eukaryotic super-family of protein kinases represents unique, strictly organized 
and precisely regulated molecules that play an important role in nearly every aspect 
of cell biology. In the human genome, about 2% of genes encode for more than 500 
distinct kinases (Manning et al, 2002). There are two main classes of kinases: 
tyrosine kinases (TKs) and serine–threonine kinases (STKs), both TKs and STKs can 
be membrane-bound and localized free in the cytoplasm and in the nucleus. There are 
90 members of the tyrosine kinase class, 58 of them being receptor tyrosine kinases 
(RTKs). All RTKs share a similar molecular structure, including extracellular ligand-
binding domain and cytoplasmic region that contains the tyrosine kinase domain. In 
brief, upon the binding of growth factor, cytokines and hormones to the receptor, the 
intracellular signalling pathways controlling cell cycle progression, development, 
differentiation, transcription and apoptosis are activated (reviewed in Lahiry et al, 
2010; Roskoski, 2014). Moreover, mutations and aberrant regulation of RTKs can 
cause constant signalling and can lead to development of a variety of pathological 
conditions including autoimmune and cardiovascular diseases, diabetes inflammation 
and cancer. The RTKs are divided into 20 subfamilies, one subfamily being the 
EGFR (epidermal growth factor receptor) family (also called the ErbB family) which 
is a family of receptors for growth factors. Excessive activation of ErbB proteins has 
been reported to be a major contributor to cancer development and progression 
(reviewed in Yarden & Pines, 2012). Shutting down the signaling may be achieved 
by downregulating an activated receptor by inducing its internalization and 
degradation. The study presented in this work aimed at increasing the understanding 
of the mechanisms controlling the internalization of ErbB2 and ErbB3. 
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Members of the EGFR/ErbB protein family  
Structure, activation, signaling  
The EGFR or ErbB family consists of four members: EGFR (also called ErbB1 or 
HER1), ErbB2 (also called Neu or HER2), ErbB3 (also called HER3) and ErbB4 
(also called HER4). The receptors are expressed in neuronal, epithelial and 
mesenchymal cells in different tissues where they play key roles in cell 
differentiation, growth and survival and they have been shown to be involved in 
development, proliferation and differentiation (reviewed in Olayioye et al, 2000). 
ErbB proteins localize mainly to plasma membrane, except ErbB3, which has been 
found at the plasma membrane and constitutively in intracellular vesicles (Sak et al, 
2012). All ErbB proteins have a large, highly glycosylated extracellular region of 
approximately 620 amino acids that can be subdivided into four domains (I-IV) 
(Figure 1). Domains I and III serve as the primary ligand-binding regions. The 
cysteine-rich domains II and IV are important for receptor dimerization where 
domain II serves as the dimerization arm and domain IV plays an auto-inhibitory role 
by interacting with domain II and keeping the dimerization arm hidden. A single 
transmembrane domain links the extracellular region to the approximately 540-
amino-acid intracellular region of the receptor that contains a tyrosine kinase domain 
as well as a carboxy-terminal tail (C-tail) of approximately 230 amino acids 
(Lemmon et al, 2014; Ward et al, 1995). The kinase domain has a bi-lobular structure 
composed of N- and C-terminal lobes which upon ligand binding and dimerization, 
adopt an asymmetric conformation where the N-lobe of one kinase domain is 
interacting with the C-lobe of the other kinase domain (Zhang et al, 2006). The C-tail 
has a regulatory role and its residual tyrosines undergo phosphorylation either by 
intrinsic (autophosphorylation) or neighbouring kinase domain 
(transphosphorylation). 
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Figure 1. ErbB proteins and their ligands. ErbB proteins share a similar structure. They 
are composed of the extracellular domain,a transmembrane segment and intracellular tyrosine 
kinase domain. Sub-domains I and III in the extracellular part of the receptor are responsible 
for ligand binding and sub-domains II and IV are involved in dimerization. In contrast to 
other ErbBs, ErbB2 doesn’t bind any known soluble ligands and it exists in a constitutively 
open conformation, while other ErbB receptors exist in a “closed” conformation in the 
absence of ligands. The kinase domain is flanked by tyrosine authophosphorylation sites and 
ErbB3 has marginal kinase activity compared with other ErbB receptors. Abbreviations: 
epidermal growth factor (EGF), transforming growth factor alpha (TGFα), epiregulin (EPR), 
heparin-binding EGF-like growth factor (HB-EGF), epigen (EPG), amphiregulin (AR), 
betacellulin (BTC), heregulin (HRG) also known as neuregulin (NRG), tomoregulin (TR). 
Adapted by permission from Nature Publishing Group: Nature Reviews Cancer (Baselga & 
Swain, 2009). The figure legend is modified.  
 
Although all ErbB proteins are very similar in their structure (Figure 1), each family 
member also has unique characteristics. EGFR, the first ErbB protein to be 
discovered (Carpenter et al, 1978), is a 175-kDa protein, and glycosylation of its 
extracellular domain  has been shown to affect ligand binding and association with 
other ErbB proteins (Tsuda et al, 2000; Whitson et al, 2005; Zhen et al, 2003). ErbB2 
is a 180-kDa protein which does not bind any known soluble ligands. Based on 
crystallographic studies it was shown that specific residues present in domain I and 
III in the extracellular part of ErbB2 interfere with ligand binding and, importantly, 
the extracellular domain has a conformation with the dimerization arm constitutively 
open (Garrett et al, 2003). This unique structure of domain II makes ErbB2 the 
EGF, TGFα, 
EPR,HB-EGF, 
EPG,AR,BTC 
HRG-1 
isoforms, 
HRG-2 α and β 
HRG-1 isoforms, 
HRG-2 α and β 
HRG-3, HRG-4 
BTC,EPR,HB-EGF 
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preferable partner for heterodimerization with other members of ErbB family and 
when ErbB2 is overexpressed it can self-associate and form functional homodimers 
(Ghosh et al, 2011). ErbB3 is a 180-kDa glycoprotein with 10 potential N-linked 
glycosylation sites (Sithanandam & Anderson, 2008). ErbB4, a 180-kDa protein, is 
the least characterized member of the ErbB family. It is distinctive among ErbB 
proteins because it can undergo proteolytic processing after ligand binding. The 
resulting intracellular fragment can then enter the nucleus and regulate gene 
transcription (Fiaturi et al, 2014; Sardi et al, 2006). Alternative splicing of the mRNA 
generates two isoforms of ErbB4 that differ in their extracellular juxtamembrane 
regions and their sensitivity to proteolytic cleavage (Elenius et al, 1997). There are 11 
growth factors in the EGF-like family (Figure 1) (reviewed in Roskoski, 2014). 
EGFR is regulated by at least seven different ligands, each contains an EGF-like 
domain that is responsible for receptor binding and activation (Harris, 2003; Lemmon 
et al, 2014). There are two ligands that bind to ErbB3 and seven ligands binding to 
ErbB4 (Figure 1), but there is no known soluble ligand that bind to ErbB2 (reviewed 
in Roskoski, 2014). All of the ligands of the ErbB family are produced as membrane-
bound precursor proteins (Buonanno & Fischbach, 2001; Harris, 2003) which are 
cleaved by cell-surface proteases, members of the ADAM (a disintegrin and 
metalloproteases) family, to yield the active growth factor species (Lemmon et al, 
2014; Roskoski, 2014). The ErbB ligands may act in an autocrine fashion on the 
same cell from which they were released, in a juxtacrine fashion on an adjacent cell, 
or in a paracrine fashion on a nearby cell, but they all act over short distance 
(reviewed in Roskoski, 2014).  
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Figure 2. Activation of the ErbB proteins. Upon ligand binding the extracellular domain of 
the ErbB receptors undergoes conformational changes leading to exposure of the 
dimerization arm (sub-domain II), receptor dimerization, activation of the tyrosine kinase 
domain and phosphorylation of the tyrosine residues in the C-terminal tail. Adapted by 
permission from Nature Publishing Group: Nature Reviews Cancer (Baselga & Swain, 2009). 
The figure legend is modified. 
 
In general, binding a ligand to the extracellular domain of the receptor allows for 
stabilization of extended conformation leading to receptor homo- or hetero-
dimerization followed by auto- or transphosphorylation of the dimerization partners 
and initiation of signaling pathways (Figure 2) (Garrett et al, 2002; Lemmon et al, 
2014; Ogiso et al, 2002; Schlessinger, 2002). Under physiological conditions, ErbB2 
homodimers are believed to be non-functional, but overexpression of ErbB2 has been 
found to form functional homodimers (Ghosh et al, 2011). Domain I in ErbB3 is a 
major contributor in ligand binding, as opposed to EGFR where the domain III is 
dominant. ErbB3’s ligands bind with higher affinity than EGFR’s (Kani et al, 2005). 
The extracellular domain of ErbB3 retains ligand binding even at acidic endosomal 
pH (in both the extended and locked conformations) (Kani et al, 2005;  reviewed in 
Sithanandam & Anderson, 2008). ErbB3 was for a long time considered to be kinase-
impaired due to the lack of several non-conserved regions in its kinase domain (Kraus 
et al, 1989; reviewed in Sithanandam & Anderson, 2008). Recent data do, however, 
show that ErbB3 is capable of binding ATP and when clustered at the plasma 
membrane it can transautophosphorylate its intracellular region (Shi et al, 2010). 
Activity of the kinase domain of ErbB3 also appears to be sufficient to phosphorylate 
other ErbB proteins in heterodimer complexes (Sak et al, 2012; Shi et al, 2010). 
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A 
 
B 
 
Figure 3. (A) The ErbB signaling pathways. Ligand binding to EGFR induces its 
dimerization and activation, leading to recruitment of multiple signaling molecules and 
activation of the following pathways: the PI3K/Akt, Ras/Raf/Mek/Erk, PLC/PKC and 
STAT and generating cellular responses including: cellular proliferation, migration and 
survival. Kinases are shown in blue, scaffolds are dark blue, adaptor proteins are yellow, 
G proteins are green and transcription factors are orange. Adapted by permission from 
Nature Publishing Group: Nature Reviews Cancer (Kolch & Pitt, 2010). The figure legend 
is modified. (B) Phosphorylation sites of the EGFR, ErbB2 and ErbB3 C-terminal 
tails. Schematic representation of the main autophosphorylation sites in EGFR, ErbB2 
and ErbB3 and of the signaling molecules associated with these sites. Adapted by 
permission from Nature Publishing Group: Nature Reviews Cancer (Hynes & Lane, 
2005). The figure legend is modified. 
 
 
 
Introduction 
 
7 
 
Signaling network activation by ErbB proteins depends on several factors: cellular 
context, receptor expression, type and availability of the ligands and the presence and 
interplay between various signaling and adaptor proteins. Ligand binding and 
receptor dimerization results in phosphorylation of tyrosine residues at specific sites 
in the C-terminal tails of the ErbB proteins (Figure 3B), which serve as docking sites 
for downstream signal transducers containing Src homology (SH2) or 
phosphotyrosine binding (PTB) domains (Yarden & Sliwkowski, 2001). This leads to 
recruitment of various downstream effectors and activation of a variety of signalling 
pathways controlling cell proliferation, differentiation, survival, migration and 
apoptosis. ErbB proteins mainly activate the phospholipase C gamma (PLCγ), the 
signal transducer and activator of transcription (STAT) pathway, the 
phosphatidylinositol 3-kinase (PI3K)-Akt and the mitogen activated protein kinase 
(MAPK) pathways (Hynes & Lane, 2005) (Figure 3A). ErbB3 contains 6 docking 
sites for direct binding of the p85 subunit of PI3K (Hellyer et al, 1998) and to some 
extent this is the reason for ErbB3’s oncogenic potency. ErbB2 has been shown to 
activate MAPK pathway through Grb2, Shc, downstream of kinase related (DOK-R) 
and CRK (Dankort et al, 2001) as well as PLCγ (reviewed in Hynes & Lane, 2005; 
Marone et al, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
8 
 
Endocytosis 
Endocytosis is a general term describing multiple pathways (Figure 4) by which cells 
control the uptake of nutrients and regulate the composition of the plasma membrane. 
Overall, the endocytic pathways can be divided into phagocytosis (or “cell eating”) 
and pinocytosis (or “cell drinking”). Phagocytosis is limited to phagocytes and is 
used for the uptake and degradation of solid particles, bacteria, and viruses. 
Pinocytosis takes place in all cell types and is typically used to internalize fluid 
surrounding the cell. Pinocytosis can be further divided into different pathways 
defined by specific molecular regulators, the presence or absence of coat proteins 
(clathrin and caveolin), and dynamin dependency.  
 
 
Figure 4. Endocytic pathways. The endocytic activities executed by cells are classified into 
pinocytosis, macropinocytosis, or phagocytosis. The various pinocytic mechanisms are 
classified according to their cellular requirements, i.e., dynamin or actin. For each 
mechanism, the major players are listed. Abbreviations: AP-2, adaptor protein 2; RhoA, Ras 
homolog gene family member A; Rac1, Ras-related C3 botulinum toxin substrate 1; GRAF1, 
GTPase regulator associated with focal adhesion kinase-1; CDC42, cell division control 
protein 42 homolog; Arf6, ADP ribosylation factor 6; PIP(5)K, phosphatidyl-inositol-5-
phosphate kinase; Fyn, a member of the protein tyrosine kinase oncogene family; Ab, 
antibody; FcR, fragment constant receptor; IL-2, interleukin-2; CLIC, clathrin-independent 
carriers; GEEC, GPI-anchored-protein-enriched endosomal compartment. Adapted by 
permission from Elsevier: Trends in Microbiology (Mercer & Greber, 2013). The figure 
legend is modified. 
 
Endocytosis is facilitated by invagination of the plasma membrane leading to the 
internalization of the membrane proteins, lipids, nutrients, and extracellular fluid. 
These cargo molecules are carried by vesicles which form by pinching off from the 
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plasma membrane (reviewed in McMahon & Boucrot, 2011). Vesicles derived from 
the plasma membrane fuse with early endosomes (EE), which are common sorting 
station for most of the endocytic mechanisms. Internalized cargo can be recycled 
back to the plasma membrane or sorted to different intracellular destinations, such as 
the trans-Golgi network (TGN) or to late endosomes (LEs)/lysosomes and designated 
for degradation. EE exhibit structural, compositional and functional heterogeneity. 
The structure of EE is characterized by the presence of morphologically distinct sub-
sub-domains that have different functions i.e. tubular extensions that will give rise to 
recycling endosomes, and large intraluminal vesicles (ILVs) that in the process of 
endosome maturation (Huotari & Helenius, 2011) will form multivesicular bodies 
(MVBs), which in turn give rise to exosomes or will be involved in degradative 
pathway (Figure 5) (reviewed in Jovic et al, 2010). The process of maturation is 
characterized by, amongst other things: membrane components exchange, endosomal 
fission, the formation of additional ILVs, decrease in luminal pH, the acquisition of 
lysosomal components and morphological alterations (reviewed in Huotari & 
Helenius, 2011).  
The sorting of various cargos is mediated by proteins and lipid components that are 
present in EE (reviewed in Jovic et al, 2010). One group of endocytic regulators 
constitute Ras-associated binding (Rab) proteins, which are small GTP-binding 
proteins that regulate endosome fusion and motility (reviewed in Stenmark, 2009). 
The Rab proteins, including Rab5 and Rab4, localize to the intracellular membranes 
in their active state and recruit other proteins, known as Rab effectors (Grosshans et 
al, 2006). One of the Rab5 effectors, the early endosomal antigen-1 (EEA1), is the 
most commonly used marker for EEs. The membrane of EE undergoes extensive 
tubulation whereby receptors that are sorted into the newly-formed tubular 
membranes recycle back to the cell surface via a “fast recycling” or “slow recycling” 
pathway (reviewed in Jovic et al, 2010). Rab4 is localized to EE and sorts receptors 
via “fast recycling” pathway back to the plasma membrane. Rab11 is known to 
associate primarily with perinuclear recycling endosomes and has been shown to 
regulate recycling of endocytosed proteins via “slow recycling” pathway (reviewed in 
Grant & Donaldson, 2009; and Jovic et al, 2010). Additionally, endosomes 
specialized for intracellular signaling are characterized by the presence of signaling 
effectors such as APPL1 and APPL2 (Adaptor protein containing PH domain, PTB 
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domain and Leucine zipper motif). APPL1 and APPL2 are associated with a subset of 
Rab5-positive EE but are not present on organelles in the canonical recycling and 
degradative pathways, and have been suggested to function primarily in signal 
transduction (reviewed in Jovic et al, 2010; Miaczynska et al, 2004). 
 
Figure 5. Endosomal sorting. Following internalization, cation-independent mannose 6-
phosphate receptor (CI-MPR), transferrin receptor (TfnR) and epidermal growth factor 
receptor (EGFR), among other receptors, enter the early endosome, where they are 
segregated into separate trafficking itineraries by a series of sorting events. TfnR is recycled 
back to the plasma membrane either through a fast recycling route or, more slowly, through 
the juxtanuclear endocytic recycling compartment. By contrast, EGFR is retained within the 
limiting membrane of the early endosome prior to undergoing ESCRT (endosomal sorting 
complex required for transport)-mediated sorting into intraluminal vesicles of the early 
endosome. These vesicles mature into late endosomes or multivesicular bodies (MVBs) that 
become competent and fuse with lysosomes, leading to EGFR degradation. Finally, CI-MPR 
is sorted for retrieval back to the trans-Golgi network through both early and late endosomal 
pathways. Adapted by permission from Nature Publishing Group: Nature Reviews Molecular 
Cell Biology from (Cullen, 2008). Illustration and figure legend are modified according to 
(Grant & Donaldson, 2009). 
 
The sorting of receptors for degradation depend on the presence of specific signals in 
their C-terminal tails, such as ubiquitination (discussed in the next paragraphs). 
Ubiquitinated cargo is captured by the endosomal sorting complex for transport 
(ESCRT) machinery and sorted into ILVs of MBV. The ESCRT machinery consists 
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of four sub-complexes: ESCRT-0, -I, -II and -III and accessory factors (reviewed in 
Hurley & Hanson, 2010; Raiborg & Stenmark, 2009). The first protein complex 
recruited to the EEs is ESCRT-0, which is composed of the two interacting proteins: 
Hrs (hepatocyte-growth-factor-reulated tyrosine-kinase substrate) and STAM 1/2 
(signal transducing adaptor molecule). Hrs and STAM bind to ubiquitinated cargo 
and to clathrin and together with Eps15 (epidermal growth factor receptor pathway 
substrate 15) stabilize the association with cargo (Bache et al, 2003b). Furthermore, 
Hrs interacts with the Tsg101 subunit of the ESCRT-I, thus recruiting it to LEs 
(Bache et al, 2003a). Next, ESCRT-II binds to ESCRT I and recruits ESCRT-III, 
leading to inward vesicle budding which is required for MVB maturation. MVBs 
eventually fuse with the lysosomes leading to receptor degradation (Henne et al, 
2011; Williams & Urbe, 2007).  
Early endosomes can, in addition to the functions mentioned above, serve as sorting 
stations for the retrograde transport of cargo from EE to TGN. Retromer machinery is 
a multimeric complex composed of subcomplexes of SNX (sorting nexin) proteins 
that are preferentially recruited to maturing EE. The main function of retromer 
complex is to recognize cargo concentrated in the EE and facilitate its sorting to the 
appropriate destination. (Bonifacino & Hurley, 2008; Cullen, 2008; Seaman, 2012; 
Wassmer et al, 2007).  
Interestingly, recent studies have devoted a lot of attention to the occurrence of 
contact sites between endosomes and the endoplasmic reticulum (ER). Besides the 
cytosolic phosphatases also the ER-localized phosphatase, PTP1B, was shown to 
dephosphorylate activated EGFR in the endosomal membrane (reviewed in Raiborg 
et al, 2015). Additionally, contact sites between the endosome and ER have been 
reported to form before endosomal fission on sites marked by a retromer-associated 
protein, indicating that endosome-ER contact sites may indirectly mediate endosomal 
sorting (reviewed in Raiborg et al, 2015). However some aspects in this field remain 
still unresolved and further elucidation of the matter could provide a clearer 
overview.  
 
 
 
 
Introduction 
 
12 
 
Clathrin-dependent endocytosis 
The clathrin-mediated endocytosis (CME) is used by all known eukaryotic cells and 
its first described physiological function was to selectively internalize receptors that 
are carrying ligands. Ligand-induced CME of many receptor (such as RTKs and G-
protein coupled receptors) often results in lysosomal degradation. However, CME of 
certain receptor can also occur constitutively, in the absence of their nutrient ligands, 
like for transferrin receptor (TfR) and low density lipoprotein receptor (LDLR), 
where upon internalization these receptors are recycled back to the plasma membrane 
(reviewed in McMahon & Boucrot, 2011).  
Clathrin has been identified as the major protein forming the lattice-like coat around 
vesicles, which were characterized as “vesicles in a basket” (Rosenbluth & Wissig, 
1964). On the cytosolic side of the plasma membrane, the clathrin-coated vesicle 
(CCV) cycle proceeds in five steps: initiation, cargo selection, coat assembly, 
scission and uncoating (Figure 6) (reviewed in Kirchhausen et al, 2014; McMahon & 
Boucrot, 2011; Traub, 2009).  
 
Figure 6. The clathrin-coated pit cycle. The formation of clathrin-coated vesicles proceeds 
through a series of steps: assembly of coat components at a designated site on the plasma 
membrane, membrane bending and cargo concentration to generate a coated pit, membrane 
scission and uncoating. Clathrin is recruited by AP‑2 and together with accessory proteins 
termed CLASPs (clathrin‑associated sorting proteins), such as epsin 1, Eps15, ARH and 
Dab2 cluster cargo molecules within the forming vesicle. Successful cargo capture is 
monitored, in part, by dynamin to prevent abortive dissolution. Clathrin-coated pit is 
pinched-off from the membrane due to action of dynamin and free, coated vesicle quickly 
moves away from the plasma membrane and is rapidly uncoated. Re‑entry of coat 
components into the soluble pool allows additional rounds of coat cycle. Adapted by 
permission from Nature Publishing Group: Nature Reviews Molecular Cell Biology (Traub, 
2009). Figure legend is modified.  
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Initiation of vesicle formation involves membrane invagination induced by adaptor 
proteins that are recruited to the site and drive budding of the clathrin-coated pit 
(CCP). Clathrin has a triskelion (three-legged) shape and is formed by three heavy 
chain subunits, each with an associated light chain subunit (Figure 7A) (reviewed in 
Kirchhausen et al, 2014; Liu et al, 1995). Clathrin does not bind directly to the 
membrane or to cargo, but relies on interaction with cytosolic adaptor protein 
complexs such as AP-2 (adaptor protein complex 2) and other accessory proteins 
(reviewed in Traub, 2009). AP-2 is a highly conserved, stable complex composed of 
four subunits: the ~100 kDa α­subunit, the ~100 kDa β2­subunit, the 50 kDa 
μ2­subunit and the 17 kDa σ2­subunit (Figure 7A) (Matsui & Kirchhausen, 1990; 
Traub, 2009). For the α-subunit, two isoforms α-1 and α-2, also known as αA and αC, 
have been identified (Ball et al, 1995). Upon phosphorylation of the μ2­subunit by 
AAK1 (AP-2 associated kinase 1), AP-2 is recruited to the plasma membrane where 
it functions as a key regulator of the maturing CCPs (Collins et al, 2002; reviewed in 
Traub, 2009). AP-2 can bind directly to endocytic motifs present in the cytoplasmic 
tail of cargo through its μ2-subunit and σ2-subunit, or indirectly through its α­ and 
β2-subunit appendage domains. AP-2 binds to inositol lipids (PIP2; PIP2 is a general 
term for Phosphatidylinositol 4,5-bisphosphate or PtdIns(4,5)P2) in the plasma 
membrane through α­ and μ2­subunits and to clathrin heavy chain (CHC) through the 
β2-subunit.  
 
A 
 
B 
 
Figure 7. (A) Structure of the clathrin triskelion and AP-2 complex. Clathrin triskelion 
is represented as a trimer of articulated legs and each leg is composed of one heavy chain 
(CHC) and one light chain (CLC). The heavy chains are joined at their C-terminal ends at a 
common hub, from which the legs spread (Ferguson et al, 2008). AP-2 is a heterotetramer 
complex composed of two large 100 kDa α- and β-subunits and two smaller, the 50 kDa μ2-
subunit and the 17 kDa σ2-subunit and α­ and β2-subunit appendage domains(Matsui & 
Kirchhausen, 1990). Adapted by permission from Nature Publishing Group: Nature (Conner 
& Schmid, 2003). The figure and figure legend is modified. (B) Structure of the dynamin. 
Dynamin consists of five functionally distinct domains, as indicated. Abrreviations: 
pleckstrin homology (PH), GTPase effector domain (GED), proline-rich domain (PRD). 
Adapted by permission from Annual Reviews: Annual Review of Cell and Development 
Biology (Schmid & Frolov, 2011).The figure and figure legend are modified. 
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However, recent studies demonstrated the existence of a so-called “putative 
nucleation module”, which assembles at the plasma membrane prior to AP-2. The 
“putative nucleation module” is composed of Eps15 and FCHo 1 and FCHo 2 
proteins (F-BAR domain-containing Fer/Cip4 homology domain only 1 and 2; F-
BAR (Bin-Amphiphysin-Rvs)), which can “sense” and bind to low curvatures in 
order to drive CCP formation (Henne et al, 2010; McMahon & Boucrot, 2011; Reider 
et al, 2009; Stimpson et al, 2009). Proteins in the nucleation module recruit AP-2 
which selects and binds to cargo together with other accessory proteins (described in 
more detail in the next paragraphs).  
CCP formation involves clathrin triskelia polymerization into hexagons and 
pentagons which stabilizes curvature and reorganizes accessory adaptor proteins 
localization, such as Eps15, to the edge of the coated pit (Kazazic et al, 2009; Tebar 
et al, 1996). Constriction of its neck is further facilitated by clathrin polymerization, 
bringing the surrounding membrane to a closed position. Vesicle scission is induced 
by polymerization of the dynamin through GTP, but the precise mechanism of the 
membrane fission is not clear yet (reviewed in McMahon & Boucrot, 2011). 
Dynamin is member of a protein family which is characterized by a highly 
homologous N-terminal GTPase domain as well as an α-helical middle domain and 
GED (GTPase effector domain) (Figure 7B). Dynamin also encodes a lipid-binding 
PH (pleckstrin homology) domain and a C-terminal PRD domain that mediates 
protein interactions with SH3 domain-containing binding partners (reviewed in 
Schmid & Frolov, 2011). Dynamin is reported to play a dual role in CME, both as a 
regulator and/or fidelity monitor during the early steps of endocytosis and facilitating 
fission of CCV from the plasma membrane (reviewed in Schmid & Frolov, 2011). 
The vesicle scission is aided by recruitment of amphiphysin, another accessory 
protein (reviewed in Ahmed et al, 2010), which binds to dynamin 2 and is responsible 
for membrane bending. Other proteins that preferentially bind to the curvatures at the 
neck of the pits and to dynamin to facilitate vesicle fission are endophilin and sorting 
nexin 9 (SNX9).  
The CCV is now irreversibly released into the interior of the cell. Uncoating, the last 
step, is initiated by synaptojanin, the lipid phosphatase that dephosphorylates PIP2 
into PI(4)P and helps to release adaptor and accessory proteins such as AP-2, epsin 
and AP-180 (described in next paragraph). Subsequent binding of ATPase heat shock 
cognate 70 (HSC70) and its cofactor, auxilin (or cyclin G-associated kinase (GAK) in 
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non-neuronal tissues) leads to disassembly of the clathrin coat from its lattice 
arrangement back to triskelia (Schlossman et al, 1984; Taylor et al, 2011). During the 
uncoating step, clathrin and other proteins are recycled back to the cytosol, where 
they can be re-used in another CCP formation cycle. The nascent vesicles undergo 
further trafficking within the cell. 
Involvement of the actin cytoskeleton in CME is still debated and it seems to be cell-
type dependent. In general, actin does not appear to be required in the early steps of 
CCP formation in mammalian cells but it can support the invagination, elongation, 
scission and movement of the CCV during the ingestion of larger cargoes (Cureton et 
al, 2009). Actin can associate with clathrin through interaction with Hip1R 
(huntingtin-interacting protein 1-related), (Chen & Brodsky, 2005; Engqvist-
Goldstein et al, 2001; Legendre-Guillemin et al, 2005). Actin can also be recruited to 
the budding vesicle following association of the actin-related complex 2/3 (Arp 2/3) 
mediated by cortactin or by N-WASP (Wiskott-Aldrich syndrome protein) (Higgs, 
2001; McMahon & Boucrot, 2011; Uruno et al, 2001).  
Sorting signals and endocytic adaptors in CME 
A wide range of activated transmembrane receptors that are internalized in a clathrin-
dependent manner carry different, unrelated sorting signals in their intracellular part, 
ranging from short peptide to whole proteins that are attached to cargoes (Traub, 
2009). Several cargo sorting motifs that are recognized by different subunits of AP-2 
have been identified, such as the YXXØ motif which binds to the μ2-subunit and is 
present in, among others, the cytoplasmic tail of TfR, and the acidic di-leucine 
[DE]XXXL[LIM] sequence which binds to the α-σ2 hemicomplex (reviewed in 
Sorkin, 2004; Traub, 2009). AP-2 was previously considered to be an obligatory 
adaptor for all clathrin-mediated endocytosis. Previous reports demonstrated that 
depletion of the AP-2 complex leads to reduced uptake of TfR, a classical marker for 
CME (Hinrichsen et al, 2003; Motley et al, 2003; Traub, 2009). It has also been 
suggested that AP-2 may not be stoichiometrically required for coat assembly, but it 
may have a more cargo-selective function in CME (Conner & Schmid, 2003). It thus 
seems that interaction with AP-2 is not always necessary for cargo recognition during 
CME and a variety of endocytic adaptors, termed CLASPs (clathrin associated 
sorting proteins), have been recognized to bind to different cargo sorting signals 
(Sorkin, 2004; Traub, 2009). CLASPs are usually mono- or dimeric proteins and 
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most of them contain domains that are able to bind to both cargo, lipid, clathrin and 
AP-2, but some are more specialized and interact either with cargo, lipids, clathrin or 
AP-2 (reviewed in Reider & Wendland, 2011) (see Table 1). One example could be 
recruitment of the LDLR that relies on recognition of its FXNPXY motif (Sallusto et 
al, 1995), by adaptor proteins Dab2 and ARH. Dab2 and ARH proteins belong to the 
PTB domain containing subfamily of CLASPs and are cargo-specific adaptors, which 
interact with AP-2 and clathrin, recruiting LDLR to clathrin coated pits (reviewed in 
Reider et al, 2009; Sorkin, 2004; Traub, 2009).  
Table 1. Endocytic adaptor proteins and their interactions
*
 
 
* Adapted with permission from Company of Biologists Ltd. (Reider & Wendland, 2011). Table is 
modified. 
 
Other examples of CLASPs are epsin1 and Eps15 which bind selectively to 
ubiquitinated cargo through tandemly arrayed UIMs (ubiquitin-interacting motifs) 
(reviewed in Traub, 2009). Epsin is an evolutionary well conserved protein with 
many homologues in lower species, like Ent1 and Ent2 that are found in yeast (De 
Camilli et al, 2002). Epsin 1 and its isoforms (epsin 2a, epsin 2b) are expressed in all 
vertebrates in many tissues and cells while epsin 3 is specifically expressed in 
keratinocytes induced by type I collagen (Spradling et al, 2001; Tessneer et al, 2013). 
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Epsin contains an evolutionary conserved domain of approximately 150 amino acids 
referred to as the ENTH domain (Epsin N-Terminal Homology), located at the  
N-terminus (Ford et al, 2002). The ENTH domain has a compact α-helical structure 
and is known to induce membrane curvature. It has been shown that binding of the 
ENTH domain to PIP2 is sufficient for stable membrane association (Itoh et al, 2001). 
The ENTH domain is followed by two or three UIMs, depending on splice variations 
(Hofmann & Falquet, 2001), while the COOH-terminal region of epsin is involved in 
recruiting components of the clathrin coat (Figure 8) (reviewed in Wendland, 2002). 
The C-terminal part of epsin is unstructured but it is characterized by the presence of 
multiple DPW motifs, which function as binding site for AP-2 (Legendre-Guillemin 
et al, 2004; Wendland, 2002). Epsin also binds to clathrin through “clathrin boxes”, 
consisting of hydrophobic and acidic residues, and to Eps15 through the NPF motif 
(Chen et al, 1999; Salcini et al, 1999). Epsin 1 has been shown to function as a cargo-
specific adaptor protein for EGF-induced internalization of EGFR but not of 
transferrin (Kazazic et al, 2009). However, the role of epsin 1 as a cargo specific 
 
Figure 8.Structure of epsin 1. The Epsin N-Terminal Homology (ENTH) domain is 
localized at the NH2-terminus of epsin and it major function is to induce membrane 
curvature. ENTH domain is followed by two or three ubiquitin-interacting motifs (UIMs), 
depending on splice variations, which bind to poly-ubiquitinated cargo. The C-terminal 
part of epsin is unstructured but it is characterized by the presence of multiple DPW 
motifs, shown as binding sites for AP-2, the “clathrin boxes”, which are responsible for 
binding to clathrin and NPF motifs, which are responsible for binding to EH-domain 
containing proteins, such as Eps15. Adapted by permission from Nature Publishing Group: 
Nature Reviews Molecular Cell Biology (Wendland, 2002). Illustration and legend are 
modified. 
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adaptor for EGFR is debated, since other reports found that epsin 1 is not needed for 
EGFR endocytosis (Huang et al, 2004). Epsin 1 is also required for the clathrin-
mediated entry of the influenza virus (Chen & Zhuang, 2008) and ubiquitinated 
MHC-I (Major histocompatibility complex class I) (Duncan et al, 2006). The 
biochemical properties of epsin establish its role as a cargo specific adaptor protein, 
but epsin also has a general function in CME and in plasma membrane remodeling 
(Boucrot et al, 2012; Ford et al, 2002; Hurley & Wendland, 2002). A recent study 
(Messa et al, 2014) suggested that the epsin proteins are essential in coordination of 
the clathrin-coat formation from its early to late stages where it links actin with 
clathrin-coated pit progression from shallow to deeply invaginated structures.  
Ubiquitination as a signal for endocytosis  
Ubiquitin is the major signal for internalization of most cargoes studied in yeast. 
However in mammalian cells, the role of ubiquitin in endocytosis is more 
complicated since not only the cargo is ubiquitinated, but also the endocytic adaptors 
and it has been shown that multiple pathways could be involved in internalization of 
ubiquitinated receptors (reviewed in Acconcia et al, 2009; and Madshus & Stang, 
2009). Ubiquitin-mediated internalization of transmembrane receptors, such as RTKs, 
requires precise molecular machinery that will recognize the ubiquitinated cargo and 
further mediate the entrance into degradative pathway. 
Ubiquitin is a small, highly conserved protein composed of 76 amino acids, which 
can be covalently attached to lysine (Lys) residues of target proteins in a 3 step 
process utilizing: Ub-activating (E1), Ub-conjugating (E2) and Ub-ligating (E3) 
enzymes (Hershko & Ciechanover, 1998; Komander, 2009; Ye & Rape, 2009). It was 
also reported that ubiquitin can be attached to cargo directly by the E2 enzyme 
(Hoeller et al, 2007). Given that ubiquitin itself contains seven Lys residues it could 
also be a substrate for ubiquitination. Monoubiquitination occurs when a single 
ubiquitin molecule is added to the target protein (Hicke & Dunn, 2003), alternatively, 
single ubiquitin molecules can bind to several Lys residues, giving rise to 
multimonoubiqitination (Haglund et al, 2003; Haglund & Dikic, 2005; Komander & 
Rape, 2012). Ubiquitin can be also added to the target protein in the form of 
polyubiquitin chains (Peng et al, 2003), which leads to the formation of structures 
with different properties depending on how the chains are assembled. It has been 
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demonstrated that chains are built sequentially, beginning with the substrate-attached 
ubiquitin. The formation of the chain can occur not only through the seven internal 
Lys residues on ubiquitin, but also through the ubiquitin N-terminus (Behrends & 
Harper, 2011; Clague & Urbe, 2010; Metzger et al, 2012; Vijay-Kumar et al, 1987). 
Polyubiquitin chains can be homogenous or mixed, linear or branched, with 
conformation depending on the type of Lys-linkage (reviewed in Komander & Rape, 
2012). Polyubiquitination via Lys48 and Lys63 are the best characterized (Hicke et 
al, 2005) (Haglund & Dikic, 2005) and it is well established that attachment of 
polyubiquitin via Lys48 targets proteins for proteosomal degradation (reviewed in 
Hershko & Ciechanover, 1998) while Lys63-linked ubiquitin chains are implicated in 
DNA repair, endocytosis, lysosomal degradation, protein translation, and cell 
signaling regulation (reviewed in Haglund & Dikic, 2005; and Komander & Rape, 
2012).  
There are three distinct classes of E3 ligases that have been identified to stimulate 
transfer of ubiquitin and ubiquitin-like proteins through either a direct or an indirect 
mechanism. The E3 ligases that mediate the direct transfer of ubiquitin from E2 to 
substrate include: HECT (the homologous to the E6AP carboxyl terminus) domain 
family (Rotin & Kumar, 2009), RING (really interesting new gene) and RING-related 
E3s, finger proteins, and members of the U-box family (Deshaies & Joazeiro, 2009; 
and reviewed in Metzger et al, 2012). The RING finger E3 ubiquitin ligase Cbl 
(Casitas B-lineage lymphoma) (Thien & Langdon, 2001) was shown to regulate 
ubiquitination of EGFR by binding directly to phosphorylated receptor tyrosine 1045, 
or indirectly through Grb2, and leading to degradation of EGFR (Levkowitz et al, 
1999; Levkowitz et al, 1998; Madshus & Stang, 2009; Waterman et al, 1999b). Cbl 
can also bind to ErbB2 but the binding is not efficient enough to target ErbB2 for 
degradation. ErbB2 downregulation has been shown to be mediated by the U-box E3 
ligase-CHIP (containing terminus Hsc 70- interacting protein) and RING E3 ligase-
Cullin5 (Xu et al, 2002). ErbB3 and ErbB4 cannot bind Cbl but it has been shown 
that Nrdp1 (neuregulin receptor degradation pathway protein 1), which is also a 
RING E3 ligase, mediates receptor ubiquitination and suppresses the levels of these 
receptors in the absence of added growth factor (reviewed in Carraway, 2010; 
Diamonti et al, 2002). NEDD4 (neural precursor cell expressed, developmentally 
downregulated 4) and Icht, which belong to HECT E3 ligases, were shown to be 
involved in mediating downregulation of ErbB4 (Carraway, 2010; Rotin & Kumar, 
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2009). Ubiquitination can be reversed due to the action of deubiquitylating enzymes 
(DUBs) that recycle ubiquitin to the cytoplasmic pool (Komander et al, 2009). Two 
endosome-localized DUBs have been identified: AMSH (associated molecule with 
the SH3-domain of STAM) and UBPY (ubiquitin-specific processing protease Y). 
AMSH is a member of the JAMM/MPN+ family of metalloproteases (Cope et al, 
2002; Maytal-Kivity et al, 2002), which have been shown to negatively regulate 
EGFR sorting to the lysosomes (McCullough et al, 2004). UBPY, also known as 
USP8, is a cysteine protease of the UBP/USP family (ubiquitin-specific processing 
protease) and has been suggested to regulate cellular ubiquitin levels and entry into S-
phase (Naviglio et al, 1998). USP8 has been proposed to be involved in regulation of 
ErbB2 (Meijer & van Leeuwen, 2011) and ErbB3 (Cao et al, 2007) trafficking, but 
involvement of USP8 in EGFR lysosomal degradation is not clear (reviewed in Maly 
& Macrae, 2014). 
 
Clathrin-independent endocytosis 
It is now clear that mammalian cells, in addition to classical clathrin-dependent 
endocytosis, utilize various other types of endocytic mechanisms, collectively termed 
clathrin-independent endocytosis (CIE). Some of these endocytic pathways are 
closely related and interact with each other, therefore inhibition of one pathway can 
up-regulate some others which in physiological conditions would play less important 
roles. These pathways employ different sets of proteins, but some studies demonstrate 
that similar, if not the same, proteins can participate in various endocytic events.CIE, 
besides macropinocytosis, include dynamin- dependent mechanisms (RhoA and 
caveolin-caveolae/lipid raft dependent) and dynamin-independent mechanisms 
(Cdc42 dependent and Arf6 dependent, also called the CLIC/GEEC pathway (CLIC, 
clathrin-independent carrier; GEEC, GPI-AP (glycosyl-phosphatidylinositol-
anchored proteins) enriched early endosomal compartment) (reviewed in Mayor et al, 
2014; Sandvig et al, 2011). 
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Macropinocytosis 
Macropinocytosis is the non-selective uptake of large areas of plasma membrane, 
nutrients, antigens and solute macromolecules. Macropinocytosis can be transiently 
stimulated by growth factors (Wang et al, 2010a) and it depends on proteins like: 
Rac, Pak1, Cdc42, CtBP1/BARS, Arf6 (Kerr & Teasdale, 2009) and sorting nexins 
(Sallusto et al, 1995) but it remains relatively inactive in most cell types (reviewed in 
Kerr & Teasdale, 2009; Sandvig et al, 2011). The most common form of 
macropinocytosis, usually occurring at cell edge, is actin-mediated, dynamin-
independent membrane ruffling. It was also demonstrated that dynamin-dependent 
formation of the macropinosome could be initiated at circular-dorsal ruffles. 
Macropinosomes are non-coated, large in size, usually > 0.2μm in diameter, 
endocytic vesicles, which ultimately deliver their content to LEs/ lysosomes or 
recycle it back to the plasma membrane. Multiple viruses (HIV-1), bacteria (for 
example Salmonella spp.) and protozoa (Leishmania amazonesis) modify and use 
macropinocytosis as the entry pathway into the host cells (reviewed in Lim & 
Gleeson, 2011). The immune system uses macropinocytosis as a means of sampling 
the environment for the presence of antigens. The antigen-presenting cells capture the 
antigens and deliver them to MHC class II-positive compartments, for degradation 
into peptides followed by recycling to the plasma membrane as MHC II-peptide 
complexes (Sallusto et al, 1995). Macropinocytosis was also suggested for uptake of 
large plasma membrane areas containing clusters of EGFR and anti-receptor 
antibodies thus allowing internalization of a large number of receptors in a single 
event (Berger et al, 2012).  
Caveolin-mediated endocytosis 
Caveolae are a special type of lipid rafts (sub-domains of the plasma membrane 
containing high concentration of cholesterol and glycoshingolipids), with a 
characteristic morphology of flask-shape invaginations of the plasma membrane 
enriched in sphingolipids, cholesterol and glycosyl phosphatidyl (GPI)-anchored 
proteins (Conner & Schmid, 2003; Mayor & Pagano, 2007). Caveolae are present at 
the surface of many mammalian cell types and are dependent on protein caveolin 1. It 
has been demonstrated that the process of caveolar budding requires Src-family 
kinases, dynamin and local actin polymerization (Sverdlov et al, 2007). Formation of 
the caveolae also depends on a complex of peripheral membrane proteins, termed 
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cavins (cavin 1, -2, -3) (Hansen & Nichols, 2010). Caveolin initially aggregates at the 
plasma membrane, cavin 3 forms a complex with cavin 1 and caveolin, stabilizing 
caveolae by linking it to actin cytoskeleton through myosin-1c (Briand et al, 2011; 
Hansen & Nichols, 2010; Parton & del Pozo, 2013). The endocytic potential of 
caveolae is controversial and it is currently being investigated (dicussed in Mayor et 
al, 2014). Current evidence suggests that caveolae can detach from the plasma 
membrane to form caveolar endocytic carriers. The majority of them are immobile, 
whereas a minority display a fast “kiss-and-run” behavior (Pelkmans & Zerial, 2005) 
and will reach the EE and then return back to the cell surface (reviewed in Gong et al, 
2008; Mayor et al, 2014). 
Clathrin- and caveolin-independent endocytosis 
Several pathways that do not require coat proteins, such as clathrin and caveolin, 
have been identified in recent years. Clathrin- and caveolin-independent pathways are 
induced and regulated by different set of proteins, giving cells greater flexibility in 
response to the extracellular stimuli. The first receptor described to follow clathrin- 
and caveolin-independent pathway was IL-2 (Interleukin 2). IL-2 internalization is 
Rho-A dependent and dynamin-independent (Lamaze et al, 2001). Flotillin 1 and 
flotillin 2 are marker proteins for another clathrin- and caveolin-independent 
internalization pathway (Glebov et al, 2006). Flotillins are a family of proteins that 
cluster preferentially in specific, cholesterol rich membrane microdomains (Rivera-
Milla et al, 2006), and whose budding occurs rarely and depends on Fyn kinase 
(Riento et al, 2009). It has been proposed that flotillins are involved in the uptake of 
lipid-associated receptors and some lipids by aggregating them outside an 
invaginated membrane that give rise to vesicles (Frick et al, 2007; reviewed in 
Sandvig et al, 2011). Flotillin1-dependent uptake of GPI-linked proteins and cholera 
toxin B was reported to be dynamin-independent (Glebov et al, 2006), but basolateral 
uptake of GPI-anchored proteins was found to be dependent on flotillin 2 and 
dynamin (Ait-Slimane et al, 2009). The internalization pathway of GPI-linked 
proteins involving flotillin 1 and flotillin 2 has been investigated more recently (Frick 
et al, 2007; Glebov et al, 2006), but previously it has been suggested that GPI-linked 
proteins were internalized by Arf1- and Cdc42-dependent pathway (Sabharanjak et 
al, 2002). The internalization of GPI-linked proteins has been observed to occur 
through tubular intermediates, termed CLICs (clathrin-independent carriers) 
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(Kirkham & Parton, 2005; Sabharanjak et al, 2002) that do not require dynamin 
activity for scission from the plasma membrane (Sabharanjak et al, 2002). It still 
remains unclear how the plasma membrane is bent into tubular structures or what 
proteins participate in detaching it from the cell surface, but it has been proposed that 
tubular budding structures are pinched off from the membrane due to synergy 
between actin and cholesterol (Howes et al, 2010). 
 
Endocytic downregulation of ErbBs  
Endocytosis is an important way of regulating ErbB-mediated signaling where 
activated receptors are internalized and either recycled back to the plasma membrane 
or targeted for lysosomal degradation, resulting in the termination of signaling. 
However, several studies have demonstrated that even when the ligand-bound 
receptor is localized to intracellular endosomal compartments, it can still serve as an 
active signaling platform (reviewed in Hupalowska & Miaczynska, 2012; Pyrzynska 
et al, 2009). Indeed, in the case of EGFR, it has also been reported that there are 
functional differences in the quality of the signaling from the EGFR localized on the 
endosomes and at the plasma membrane. Whereas EGFR localized at the cell surface 
was reported to mediate proliferative signaling, the EGFR on the endosomes was 
observed to activate apoptosis (Burke et al, 2001; Hyatt & Ceresa, 2008; Rush et al, 
2012; Wang et al, 2002).  
Endocytic downregulation of EGFR 
Endocytosis of activated EGFR was one of the first ligand-induced endocytic 
pathways to be discovered and became a prototypical model system for all RTKs. 
The turnover of EGFR (or the half-life of the protein) in cells expressing moderate 
levels of this the receptor varies in the range of 6-10 h (Beguinot et al, 1984; 
Stoscheck & Carpenter, 1984b), reaching up to 24 h in cells overexpressing EGFR 
(Stoscheck & Carpenter, 1984a). EGFR can undergo internalization and recycling in 
the absence of ligand but the rate of its internalization is slow. It has been shown that 
EGFR is internalized via CME (Carpentier et al, 1982; Hanover et al, 1984). 
However there are conflicting results regarding the requirement of AP-2 for 
endocytosis of EGFR. Some reports show that endocytosis of EGFR is inhibited in 
the absence of AP-2 (Huang et al, 2004; Johannessen et al, 2006), while others 
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(Conner & Schmid, 2003; Motley et al, 2003) state that the entry of EGF can proceed 
independently of AP-2. Additionally, EGFR has been reported to undergo 
internalization via CIE (Hinrichsen et al, 2003; Sigismund et al, 2005) and in some 
cell lines activation of EGFR has been shown to increase membrane dynamics and 
ruffling leading to macropinocytic uptake of EGFR (Chinkers et al, 1979; Orth et al, 
2006), but the kinetic rates were much slower that for those observed for CME 
(reviewed in Sorkin & Goh, 2008). The type of bound ligands can regulate the 
intracellular sorting and downregulation of EGFR. Upon internalization and 
acidification of the endosomes EGF remains bound to EGFR (Sorkin & Waters, 
1993), whereas TGF-α dissociates from the receptor at much higher pH (Ebner & 
Derynck, 1991). Consequently, binding of EGF targets EGFR for the degradative 
pathway due to prolonged phosphorylation and ubiquitination while TGFα-induced 
activation results in recycling of the receptor back to the cells surface (Longva et al, 
2002). Moreover it was demonstrated that while EGF and TGFα induce CME, HB-
EGF and BTC induce CIE (Henriksen et al, 2013) and target EGFR to lysosomes 
(Roepstorff et al, 2009). In addition, the involvement of ubiquitination in endocytosis 
of EGFR has been discussed. Some studies showed that ubiquitination of EGFR is 
not necessary for its internalization, especially at low doses of EGF, which do not 
induce detectable EGFR ubiquitination (Sigismund et al, 2005). On the contrary, 
other studies demonstrated that EGFR is ubiquitinated also at low concentrations of 
EGF, and that epsin 1 interacts with ubiquitinated EGFR (Kazazic et al, 2009). Our 
group discovered that ubiquitination of EGFR occurs already at the plasma 
membrane (Stang et al, 2000) and later reports showed that upon stimulation with 
EGF, EGFR becomes multimono- and polyubiquitinated, the latter mainly via Lys63- 
but also via Lys48-linked polyubiquitin chains (Huang et al, 2006; Umebayashi et al, 
2008). CIE was also postulated to be an endocytic route used for downregulation of 
activated EGFR. Sigismund et al. reported that at high concentrations of EGF, EGFR 
was found to co-localize with caveolin 1, but it not necessarily indicated that 
internalization of EGFR occurs through caveolae (Sigismund et al, 2005). However, 
Kazazic et al. found that high concentrations of EGF do not recruit EGF-EGFR into 
caveolae nor increase the basal levels of caveolar endocytosis and that despite the 
concentration of EGF, CME is the main pathway used for EGFR internalization 
(Kazazic et al, 2006). Later, Sigismund et al. (Sigismund et al, 2008) found that CIE 
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of EGFR is in fact independent of caveolin 1 and further demonstrated that at low 
concentrations of EGF, CME plays a major role in recycling EGFR to the cell 
surface, and only a minor role in degradation. On the other hand, they reported that at 
high concentrations of EGF, CME is still operating, but a major portion of EGFR is 
ubiquitinated and internalized through CIE, which in turn leads to its efficient 
degradation, protecting the cell from overstimulation (Sigismund et al, 2008). It has 
been suggested that these differences could arise due to the different cell lines used 
by different groups. In some cell lines that express moderate or low levels of EGFR, 
CME is the main pathway used to internalize EGFR, at both low and high 
concentrations of EGF (Kazazic et al, 2009). However, in cases of EGFR 
overexpression and high doses of the ligand, CME becomes saturated (Lund et al, 
1990; Sorkin & Goh, 2008; Wiley, 1988) and it has been proposed that CIE takes 
over the uptake of EGF (Sigismund et al, 2008; Sigismund et al, 2005; Sorkin & Goh, 
2008). 
Endocytic downregulation of ErbB2 
Early studies showed that the kinase domain of ErbB2 is activated and 
phosphorylated but that ErbB2 is less efficiently internalized than EGFR due to its C-
terminal domain that either does not possess all the signals required for rapid 
internalization or contains a signal that inhibits rapid internalization (Sorkin et al, 
1993). The precise mechanisms for inefficient endocytosis of ErbB2 are still debated 
(reviewed in Bertelsen & Stang, 2014). Later reports have shown that, on the one 
hand, ErbB2 undergoes slow internalization and rapid recycling (Austin et al, 2004) 
but on the other hand, it is retained at the plasma membrane where it is concentrated 
on cellular protrusions (Hommelgaard et al, 2004) and in lipid rafts (Nagy et al, 
2002) and only minor amounts of ErbB2 were found in endosomal compartments, 
even when overexpressed (Lerdrup et al, 2006; Longva et al, 2005). It has been 
shown that ErbB2 interacts with lipid-raft associated flotillins and that this interaction 
stabilizes ErbB2 at the cell surface (Pust et al, 2013). In addition, it has been shown 
that ErbB2 is stabilized at the plasma membrane by the Cdc37-Hsp90 complex 
through direct interactions with the catalytic domain of the receptor (Raja et al, 
2011). Hsp90 (Heat shock protein complex 90) is a major chaperone involved in 
quality control of newly synthesized proteins (Taipale et al, 2010) and the specific 
interactions between Hsp90 and their clients are regulated by various co-chaperones, 
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such as Cdc37 (Pearl, 2005). One way to inhibit Hsp90 is by the use of GA 
(Geldanamycin) or its derivatives, such as 17AAG (17-allylaminogeldanamycin), 
which also downregulates ErbB2 (Austin et al, 2004; Lerdrup et al, 2006; Pedersen et 
al, 2008). The study of Austin et al. (Austin et al, 2004) concluded that the GA-
induced inhibition of Hsp90 caused downregulation of ErbB2 by inhibiting recycling 
and increasing lysosomal sorting, but not by increased internalization. However, later 
reports show that GA and 17AAG induce internalization of ErbB2, mainly through 
CME (Cortese et al, 2013; Pedersen et al, 2008; Vuong et al, 2013). Baulida et al. 
(Baulida et al, 1996) showed that ErbB2 does not interact with the adaptor complex 
AP-2 however, this does not exclude interaction with other CLASPs. The studies of 
both Lerdrup et al. (Lerdrup et al, 2006) and Pedersen et al. (Pedersen et al, 2008) 
showed that Hsp90 inhibitors can induce caspase- and/or proteasome-mediated 
cleavage of ErbB2. Later report of Lerdrup et al. (Lerdrup et al, 2007) demonstrated 
that upon incubation with GA, the C-terminus of ErbB2 is cleaved and is 
accompanied by proteasome-dependent endocytosis of ErbB2, which is in contrast to 
the studies of Pedersen et al. who demonstrated that upon GA treatment, ErbB2 is 
internalized as a full length protein. However, these studies are in agreement claiming 
that the overall GA-induced degradation of ErbB2 depends on proteasomal activity. 
Moreover, Pedersen et al. found that proteosomal activity is required for transport of 
ErbB2 from the limiting membrane to inner vesicles of MVBs but that ErbB2 itself is 
not the proteosomal target (Pedersen et al, 2008). Furthermore, GA-treatment was 
early reported to induce ubiquitination of ErbB2 (Mimnaugh et al, 1996) and later on 
it has been shown to disrupt ErbB2-Hsp90 complex with simultaneous recruitment of 
Hsp70 (Xu et al, 2001) along with the ubiquitin E3 ligases CHIP and Cullin5 (Xu et 
al, 2002; Zhou et al, 2003) to ErbB2. Recently our group (Vuong et al, 2013) found 
that an ErbB2-ubiquitin chimera (ErbB2-Ub4) was constitutively endocytosed and 
degraded via CME which supports the role of ubiquitination as a signal for 
endocytosis of ErbB2. Furthermore, the internalization of ErbB2-Ub4 as well as wild-
type ErbB2 has been shown to depend on epsin 1 and Eps15 (Vuong et al, 2013). The 
Cbl proteins (reviewed in Schmidt & Dikic, 2005), which are involved in ligand-
induced EGFR ubiquitination and downregulation, were also reported to bind to 
ErbB2 (Carraway, 2010; Sorkin & Goh, 2008). However, binding of Cbl to ErbB2 
was reported to be inefficient in induction of ubiquitination and degradation of ErbB2 
(Citri et al, 2003).  
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Endocytic downregulation of ErbB3 
Little is known about endocytosis of ErbB3 when compared to EGFR and ErbB2. 
ErbB3 has relatively short half-life, estimated to be between 2,5 and 3,5 hours (Cao et 
al, 2007; Warren et al, 2006; Waterman et al, 1998). ErbB3 was thought to be 
endocytosis impaired since it doesn’t bind to AP-2 (Baulida & Carpenter, 1997; 
Baulida et al, 1996). However, later studies demonstrated low rate of ligand-
dependent ErbB3 internalization (Baulida & Carpenter, 1997). The studies of 
Waterman et al. showed that, upon stimulation with ligand, ErbB3 was endocytosed 
and recycled back to the cell surface instead of being degraded (Waterman et al, 
1999a). The reason for lack of lysosomal sorting was reported to be due to missing 
sorting signals in the C-terminal tail of ErbB3. Further on, the study of Warren et al. 
demonstrated that binding of the full length HRG, heregulin-extracellular domain 
(HRG-ECD), composed of EGF-like domain and the N-terminal IgG-like domain, 
sterically interfere with the formation of larger order oligomers from dimers and 
disrupts ErbB3 oligomers at the plasma membrane leading to enhanced 
downregulation of ErbB3. However, the mechanisms underlying the disruption of 
higher order complexes were not investigated. Furthermore, they reported that the 
short version of HRG, composed of EGF-like domain only, is both necessary and 
sufficient for initial binding and activation of ErbB2-ErbB3 heterodimers (Warren et 
al, 2006). The study of Cao et al. demonstrated that cellular levels of ErbB3 can be 
suppressed by factors, such as HRG, which controls stability of Nrdp1 which in turn 
mediates ubiquitination of ErbB3. They further reported that HRG stimulation leads 
to stabilization of USP8, which deubiquitinates Nrdp1 and thus targets ErbB3 for 
ligand-induced degradation (Cao et al, 2007). Besides HRG-induced internalization, 
ErbB3 was also shown to localize to intracellular vesicles in the absence of added 
ligand (Lemoine et al, 1992; Prigent et al, 1992; Sak et al, 2012), and more recently 
the constitutive internalization of ErbB3 was found to occur via CME (Sak et al, 
2012). However, the exact mechanisms and requirement for specific adaptor proteins 
still remains under investigation. Previously, the study of Diamonti et al. (Diamonti 
et al, 2002) reported that Nrdp1 is the main component responsible for maintaining 
steady-state levels of ErbB3 by regulating constitutive internalization of ErbB3 and 
directing it to lysosomal degradation. However, it has also been demonstrated that 
Nrdp1 associates with ErbB3 and stimulates its ubiquitination and degradation by 
proteasomes (Qiu & Goldberg, 2002). Recently another E3 ligase, NEDD4, has been 
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reported to interact with ErbB3 in a ligand-independent manner, and when NEDD4 
was inhibited by siRNA, the levels of ErbB3 were elevated, leading to increased 
ErbB3-mediated signaling (Huang et al, 2015). It was also demonstrated that ErbB3 
in its nascent, not mature form was found to interact with Hsp90 (Gerbin & Landgraf, 
2010). The recent report of Asp et al. (Asp et al, 2014) reported that GA-induced 
inhibition of Hsp90 caused ErbB3 degradation, but no studies so far have 
demonstrated direct, physical interaction between Hsp90 and full length ErbB3. 
Moreover, the study of Asp et al. demonstrated that ErbB3, like ErbB2, is stabilized 
at the cell surface by interaction with flotillins (Asp et al, 2014).  
 
ErbB proteins in cancer 
The ErbB proteins regulate cellular growth, migration, and survival under normal 
physiological conditions but it has also been demonstrated that ErbB proteins can 
play important roles during tumor progression. ErbB proteins are implicated in many 
human cancers in many ways. Point mutations and overexpression of the receptors or 
overproduction of ligands can cause constitutive activation or defective degradation 
of the ErbB proteins (Hynes & MacDonald, 2009; Tebbutt et al, 2013). 
Overexpression of EGFR due to gene amplification was shown to be involved in the 
pathogenesis and progression of different types of carcinoma including: lung, breast, 
head and neck, ovarian, gastric cancers (reviewed in Yarden & Pines, 2012). 
Mutations in EGFR, most frequently deletion in the extracellular domain, which is 
denoted EGFRvIII, are present in many cancer types (Sugawa et al, 1990). EGFRvIII 
is constitutively active and upon internalization it is recycled back to the cell surface, 
escaping ubiquitination and lysosomal degradation, leading to sustained oncogenic 
signaling (Grandal et al, 2007). Sustained signaling through EGFR is also caused by 
overexpression of ErbB2 and was shown to inhibit endocytosis and degradation of 
EGFR (Haslekas et al, 2005). Interestingly, it has also been reported that EGFR can 
localize to other organelles, for example it can be translocated from the plasma 
membrane to the nucleus through a retrograde pathway from the Golgi to ER (Wang 
et al, 2010b). EGFR, but also ErbB2 have been found in the nucleus to function as 
transcriptional regulators of cancer-related genes and promote cancer growth 
(reviewed in Han & Lo, 2012). 
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Dimerization of one of ErbB member with other RTKs may enhance its oncogenic 
activity. Heterodimerization of ErbB2 and ErbB3 activates the PI3K/Akt signaling 
pathway through ErbB3 and triggers proliferation and survival of human cancers. 
This pathway plays an important role in the development of various human cancers, 
including ErbB2-overexpressing breast cancer (Holbro et al, 2003; Lee-Hoeflich et 
al, 2008), prostate cancer (Jathal et al, 2011), ovarian cancer (Mills & Yarden, 2010) 
and non-small cell lung cancer (NSCLC) (Engelman et al, 2007; Huang et al, 2013). 
In addition to full length ErbB2, truncated forms of ErbB2 (p95HER2) that are 
generated by ADAM-mediated proteolytic cleavage or during translation from 
internal translation codons (Tse et al, 2012; Zagozdzon et al, 2011), have been 
reported to be present in a subgroup of ErbB2-positive cancers (reviewed in Bertelsen 
& Stang, 2014; Christianson et al, 1998). The oncogenic function of ErbB3 is mostly 
mediated through overexpression and interaction with EGFR or ErbB2. ErbB3 is 
overexpressed in several cancer types, including pancreatic, breast, ovarian and 
gastric cancers (reviewed in Sithanandam & Anderson, 2008). Although it has been 
demonstrated that ErbB3 overexpression is associated with poor prognosis in patients 
with breast cancer, it has also been reported that ErbB3 overexpression may be a 
positive prognostic factor (reviewed in Koutras et al, 2010). A naturally occurring 
secreted form of the ErbB3 receptor, p85-soluble ErbB3 has been shown to be a 
potent negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 
activation (Lee et al, 2001). 
ErbB-targeted therapeutics 
The increased expression of growth factor receptors during tumorigenesis can be used 
as pharmaceutical targets for targeted therapies in treatment of human cancers. 
Targeted therapeutics, when used in combination with standard therapy, can help to 
improve clinical anti-tumor response to chemotherapy by blocking ligand binding 
and shutting down the signaling that occurs through growth factor receptors (Weiner 
et al, 2010). The frequent activation of ErbB family members in cancer makes them 
attractive targets for design of such therapeutics (overview in Figure 9). Several ErbB 
agents have been developed to target mostly EGFR and ErbB2 (Figure 9), since these 
two receptors have the best-defined roles in cancer, and are approved for the 
treatment of various solid tumors (reviewed in Sliwkowski & Mellman, 2013). 
Therapeutics targeting ErbB proteins are divided into two main classes: monoclonal 
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antibodies (mAbs) that bind to extracellular domain, and low molecular weight 
tyrosine kinase inhibitors (TKIs) that bind to intracellular tyrosine domain. Another 
class of agents targeting ErbB proteins include heat-shock protein (Hsp) inhibitors, 
such as 17AAG and antibody-drug conjugates (ADCs), such as T-DMI (trastuzumab 
conjugated to maytansine derivative (DM1)) (reviewed in Sliwkowski & Mellman, 
2013). Also other small molecule inhibitors that bind to ErbB signaling molecules 
exist (reviewed in Hynes & MacDonald, 2009) (overview in Figure 9). 
 
Figure 9. The ErbB signaling- targeted therapeutics. Overview of monoclonal antibodies 
(mAb) and tyrosine kinase inhibitors (TKIs) specifically targeting the ErbB family members 
(described in more detail in the text). Adapted by permission from Nature Publishing Group: 
Nature Reviews Cancer (Yarden & Pines, 2012). Figure legend is modified.  
Monoclonal antibodies 
One of the most effective strategies in targeted therapies involves the use of 
recombinant proteins, usually mAbs that target proteins which are expressed at the 
cell surface. mAbs that are used in therapy are genetically engineered by combining 
genes from multiple sources of B lymphocytes (mostly mouse and human), human 
immune cells, or coupled phage or yeast display libraries (reviewed in Sliwkowski & 
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Mellman, 2013). The adopted approach makes it possible to avoid the immune 
response in humans, which otherwise could be triggered by the use of antibodies 
produced in mice. Mechanisms that underlie the antitumor activity of mAbs (Figure 
10) include binding to the extracellular part of the specific receptor, which in turn can 
interfere with ligand binding and dimerization with other receptors. Other antibodies 
can, upon binding to the certain receptor, induce its internalization and degradation 
(Zhou et al, 2011). Moreover, it has been shown that combination of a minimum of 
two antibodies with non-competitive binding sites enhanced the efficient 
internalization of the targeted receptor (Ben-Kasus et al, 2009; Hughes et al, 2012; 
Pedersen et al, 2015). Furthermore, mAbs can trigger antibody-dependent cellular 
cytotoxicity (ADCC) and recruit immune cells, such as NK cells, macrophages, and 
neutrophils, leading to the apoptosis of tumor cells (reviewed in Weiner et al, 2010) 
(Figure 10). 
Anti-EGFR monoclonal antibodies 
EGFR was one of the first growth factor receptors used as a target in cancer therapy 
(Gschwind et al, 2004). Cetuximab (Erbitux
®
) is a human-mouse chimeric IgG1 mAb 
that binds to domain III in the extracellular part of inactive EGFR preventing the 
receptor from adopting the open conformation (Li et al, 2005) and blocking binding 
of the ligand. It has been demonstrated that binding of cetuximab can induce 
internalization of EGFR (Jaramillo et al, 2006; Sunada et al, 1986) and induce ADCC 
(Kimura et al, 2007). Cetuximab is approved for the treatment of wild type K-RAS 
EGFR-expressing metastatic colorectal cancer. Nimotuzumab (TheraCIM
®
), a 
humanized IgG1 mAb that binds to EGFR domain III, has been shown to display 
similar mechanisms of action to cetuximab, while only partially inducing ADCC 
(reviewed in Friedlander et al, 2008). Panitumumab (Vectibix
™
) is a fully human 
IgG2 mAb that binds to EGFR’s domain III with higher affinity than cetuximab, 
preventing binding of the ligand. Panitumumab inhibits EGF-dependent tumor cell 
activation, EGFR tyrosine phosphorylation, and cell proliferation but is less effective 
in mediating ADCC than cetuximab (Astsaturov et al, 2006; and reviewed in 
Sliwkowski & Mellman, 2013). Panitumumab is approved for treatment of multiple 
EGFR-expressing human solid tumors, with wild type K-RAS (Weiner et al, 2008) 
(overview in Figure 9). 
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Anti-ErbB2 monoclonal antibodies 
Monoclonal antibodies that are approved for treatment of ErbB2-positive breast 
cancer include trastuzumab (Herceptin
®
) and pertuzumab (Perjeta®), (see overview 
Figure 9 for an overview) (reviewed in Sliwkowski & Mellman, 2013). Trastuzumab 
is a humanized IgG1 mAb that binds to the extracellular domain IV of ErbB2 (Carter 
et al, 1992). However the exact mechanisms of its anti-tumor activity are not 
completely understood. In the early reports trastuzumab has been reported to prevent 
dimerization of ErbB2 with other ErbB proteins which resulted in reduced signaling 
from ErbB2 (Klapper et al, 1997). Later it has been observed that trastuzumab 
inhibited the PI3K signaling pathway, caused cell cycle arrest and inhibited 
proliferation (Sliwkowski et al, 1999), and induce ADCC (Weiner & Adams, 2000). 
On one hand it has been suggested that trastuzumab induces internalization and 
degradation of ErbB2 (Baselga et al, 2001), but on the other hand, others did not 
observe trastuzumab-induced internalization of ErbB2 (Longva et al, 2005). 
Trastuzumab was also reported to block metalloprotease cleavage of ErbB2, which 
prevents formation of p95HER2, a truncated form of ErbB2 (Molina et al, 2001). 
Contrary to trastuzumab, anti-tumor activities of pertuzumab, another therapeutic 
antibody against ErbB2, are better characterized. Pertuzumab is a fully humanized 
IgG1 mAb that binds to domain II of ErbB2 preventing its dimerization with other 
receptors (Franklin et al, 2004). It has been shown that pertuzumab together with 
trastuzumab and 17AAG induced efficient internalization and degradation of ErbB2. 
Moreover, the combination of pertuzumab, trastuzumab and 17AAG increased the 
inhibitory effect on Akt activation of each of these agents (Hughes et al, 2012). 
Pertuzumab was demonstrated to inhibit ligand-induced ErbB2-EGFR 
heterodimerization and to facilitate EGF-induced internalization and degradation of 
EGFR in cells overexpressing ErbB2 (Hughes et al, 2009). In paper I we have 
observed similar effects of action of pertuzumab on HRG-induced ErbB2-ErbB3 
heterodimerization, where pertuzumab has been shown to prevent ErbB2-ErbB3 
heterodimers formation and inhibit ErbB3 phosphorylation in cells overexpressing 
ErbB2. In addition, it has been reported that pertuzumab blocked HRG-induced 
ErbB2-ErbB3 heterodimerization leading to reduced phosphorylation of ErbB3 and 
MAPK and Akt signaling, thus inhibiting growth of cancer cells (Sakai et al, 2007). 
Pertuzumab was also shown to mediate ADCC (Yamashita-Kashima et al, 2011). 
mAbs targeting ErbB2 have proven to be efficient in the treatment of ErbB2-positive 
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breast cancer patients. Dual blockage of ErbB2 by two mAbs has been shown to be 
active in early breast cancer and late-stage metastatic breast cancer and produced an 
overall better clinical outcome (reviewed in Sliwkowski & Mellman, 2013). The 
combination of two anti-ErbB2 mAbs together with conventional methods, such as 
chemotherapy, is even more efficient in the treatment of ErbB2-positive breast cancer 
patients than each agent alone. Pertuzumab is approved in combination with 
trastuzumab and docetaxel for the treatment of patients with ErbB2-positive 
metastatic breast cancer without prior treatment with anti-ErbB2 therapy for 
metastatic disease. Moreover, this combination was also approved for neoadjuvant 
therapy in ErbB2-positive patients with locally advanced, inflammatory, or early 
stage breast cancer (Baselga et al, 2012; Maly & Macrae, 2014; Moasser & Krop, 
2015). In addition, mAbs can also be used as vehicles for the selective delivery of 
cytotoxic agents to tumors. One example is T-DM1 which is composed of 
trastuzumab (T) conjugated to maytansine derivative (DM1) (Lambert & Chari, 
2014). It has been proposed that a trastuzumab conjugate simply uses ErbB2-
overexpressing cells as a target for the delivery of a potent cytotoxic agent, which is 
released only after limited digestion of the entire antibody (Lewis Phillips et al, 
2008). T-DM1, which has recently gained approval for use, was reported to prolong 
progression-free survival in late-stage ErbB2-positive breast cancer patients for 
whom other treatments have failed (reviewed in Sliwkowski & Mellman, 2013). 
Anti-ErbB3 monoclonal antibodies 
ErbB3 is one of the most potent activators of the PI3K/Akt pathway and is 
upregulated and transphosphorylated in several forms of cancer, in particular 
following treatment with EGFR and ErbB2 inhibitors. In past years, several mAbs 
targeting ErbB3 have been developed. MM-121, is a human IgG2 mAb that binds 
specifically to ErbB3 and is able, directly or indirectly, to block ligand–induced 
receptor heterodimerization with ErbB2, and to inhibit HRG-induced ErbB3 and Akt 
phosphorylation (reviewed in Aurisicchio et al, 2012). However, MM-121 is mainly 
active in cancers with ligand-dependent activation (Schoeberl et al, 2010). Currently, 
MM-121 is being assessed in Phase I and II clinical trials in breast cancer, non-small 
cell lung cancer, ovarian cancer as well as other solid tumor cancers (reviewed in 
Aurisicchio et al, 2012). AMG 888, a human anti-ErbB3 mAb, has been also shown 
to block ErbB3-induced Akt and Erk signaling and to inhibit growth of several tumor 
Introduction 
 
34 
 
cell lines alone, but it proved to work better in combination with other ErbB family 
inhibitors (reviewed in Aurisicchio et al, 2012). TK-A3 and TK-A4, both IgG1 
mouse anti-ErbB3 mAbs, have been shown to modulate the growth rate of different 
cancers. TK-A3 and TK-A4 were found to inhibit receptor recycling to the cell 
surface, block ligand binding and induce receptor internalization and degradation 
(reviewed in Aurisicchio et al, 2012; Belleudi et al, 2012). Another interesting 
example of mAbs is MEHD7945A, which is a human dual specific anti-ErbB3 and 
anti-EGFR mAb that has been shown to inhibit EGFR- and ErbB3-mediated 
signaling in vitro and in vivo and to induce ADCC (Schaefer et al, 2011). However, it 
has been found to act mainly by blocking ligand binding and setting the receptors in a 
closed conformation (reviewed in Aurisicchio et al, 2012). Analogous bi-specific 
antibody, MM-111 that binds simultaneously to both ErbB2 and ErbB3, has been 
shown to block signaling and tumor growth (McDonagh et al, 2012). 
Tyrosine Kinase Inhibitors and other inhibitors 
The second major class of therapeutics targeting ErbB family members is low 
molecular weight tyrosine kinase inhibitors (TKIs) that compete reversibly or 
irreversibly with ATP binding to the kinase domain of ErbB proteins (overview in 
Figure 9). Only a few specific TKIs to receptor tyrosine kinase family have been 
developed for the treatment of cancer patients. Although, it has been shown that TKIs 
have numerous, partly severe side effects, TKIs serve as additional options in second-
third- and/or fourth-line therapy (Eckstein et al, 2014). Gefitinib (Iressa®) (Herbst et 
al, 2004) and erlotinib (Tarceva
®
) (Minna & Dowell, 2005) are reversible, selective 
EGFR-TKIs that preferentially bind the kinase in the active conformation. Anti-tumor 
effects of gefitinib and erlotinib have been investigated in many tumors 
overexpressing EGFR and most trials failed to show potent clinical effects. However 
there are some exceptions, as for patients with non-small cell lung cancer that contain 
mutations in the kinase domain of EGFR, who responded well to EGFR-TKIs 
(reviewed in Tebbutt et al, 2013). Skin rash is one of the most common adverse 
effects associated with the inhibition of EGFR and this reaction is considered as a 
biomarker of EGFR inhibition. Although, is not universally accepted as a clinical 
response, patients who develop rashes tend to more likely exhibit therapeutic effects 
(Saif & Kim, 2007; and reviewed in Sliwkowski & Mellman, 2013). There are no 
specific ErbB2-TKIs, but lapatinib (Tykerb/Tyverb
®
), afatinib (Gilotrif™) and 
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neratinib are TKIs that inhibits both EGFR and ErbB2. Lapatinib is a reversible TKI 
that binds to kinase-inactive conformation of EGFR. Lapatinib has been shown to 
inhibit EGF-stimulated phosphorylation of Akt in ErbB2-overexpressing human 
breast cancer cell line and EGF-stimulated phosphorylation of EGFR and Akt in 
human head and neck cancer cells that overexpress EGFR (reviewed in Tebbutt et al, 
2013). It has also been demonstrated that lapatinib can induce apoptosis of tumor 
cells in vitro and in vivo in xenografted mice with cell lines over-expressing EGFR 
and ErbB2 (reviewed in Hojjat-Farsangi, 2014; Rusnak et al, 2001; Xia et al, 2002).  
In addition to TKIs, several small-molecule inhibitors targeting Hsp90 (Figure 9) are 
now in clinical investigation in a wide range of cancer types (reviewed in Jhaveri et 
al, 2012). Hsp90 is an important target in cancer therapy because many of its clients 
constitute oncoproteins, such as ErbB2, with important functions in the development 
and promotion of cancer. GA, originally pursued as an antibiotic, was later shown to 
bind directly to Hsp90 and interfere with Hsp90-v-src heterocomplex formation 
(Whitesell et al, 1994). GA competes with ATP in binding to the N-terminal domain 
of Hsp90, which results in inhibition of Hsp90 activity followed by ubiquitination 
and degradation of its clients (Pearl et al, 2008). GA is not suitable as a clinical agent 
because of its poor solubility, limited in vivo stability and significant hepatotoxicity 
in animals (Neckers, 2006), but it serves as a “model” molecule for other agents that 
are now in clinical trials (reviewed in Jhaveri et al, 2012). 17AAG a less toxic 
derivative of GA is an Hsp90 inhibitor that has been extensively studied for targeting 
oncoproteins. It was demonstrated that 17AAG inhibits cell growth and induces 
apoptosis (Munster et al, 2002; Solit et al, 2002). Currently, there are approximately 
15 other, besides 17AAG, Hsp90 inhibitors in clinical trials (Barrott & Haystead, 
2013). 
Resistance to ErbB-targeted therapies 
Resistance to therapies targeting ErbB proteins is currently a common limitation of 
such treatment. There are two types of resistance: intrinsic resistance that includes the 
factors that exist before treatment and acquired resistance that develops during 
treatment of tumor cells (reviewed in Holohan et al, 2013). Numerous mechanisms of 
acquired resistance have been reported, such as loss of tumor suppressors, additional 
mutations and overexpression of oncoproteins, such as ErbB proteins and their 
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ligands, and other signal receptors. Loss of expression or inactivation of PTEN 
(phosphatase and tension homolog) was found to be one of the reasons for acquired 
resistance to trastuzumab, lapatinib and gefitinib (Wheeler et al, 2010). Formation of 
EGFR-ErbB3 and ErbB2-ErbB3 heterodimers was shown to accelerate proliferation 
of cancer cells and failed to respond to targeted therapies against EGFR and ErbB2 
due to compensatory activation of ErbB3-dependent signaling pathways. Cetuximab, 
gefitinib and erlotinib are ineffective in patients with K-RAS mutations because these 
anti-EGFR drugs cannot suppress EGFR-independent MAPK survival signaling 
(reviewed in Ciardiello & Tortora, 2008; Tsujioka et al, 2010). In addition, acquired 
resistance to EGFR targeted therapy is caused by development of an additional EGFR 
mutation, T790M, which causes structural changes in the tyrosine kinase domain of 
EGFR preventing erlotinib and gefitinib from binding to EGFR (Pao et al, 2005). 
Unfortunately, 50-60% of metastatic breast cancer patients appear resistant to 
trastuzumab (Romond et al, 2005). The mechanisms of trastuzumab resistance 
include activation of alternative signaling from other ErbB proteins, insulin-like 
growth factor receptor (Liu et al, 2011), activation of PI3K/Akt/mTOR or loss of 
PTEN (Saal et al, 2005), overexpression of c-MET (Shattuck et al, 2008), up-
regulation of Src activity (Rexer & Arteaga, 2012) or MUC4 (Mukhopadhyay et al, 
2011), increased VEGF (vascular endothelial growth factor) expression (Yang et al, 
2002) and expression of the p95 isoform of HER2 (Gallardo et al, 2012). p95HER2 is 
expressed in nearly 30% of ErbB2-positive breast cancers and despite lacking an 
extracellular domain, p95HER2 still triggers proliferative downstream signaling 
events and forms potent heterodimers due to its active kinase region (Arribas et al, 
2011). The absence of the extracellular domain eliminates mAb-targeted therapies 
and constitutes a cause of resistance to such drugs. However, p95HER2 remains 
susceptible to kinase inhibition and the use of TKIs serves as an important way to 
overcome antibody resistant therapies (Schroeder et al, 2014).  
There are several ways to enhance efficiency of inhibition of ErbB proteins and to 
overcome the acquired resistance to ErbB-targeted therapies:  
1) Dual targeting of extra- and intracellular parts of ErbB proteins that will enhance 
their inhibition (more in Figure 10a). It was also shown that simultaneous use of 
both mAb and TKIs alters receptor conformation and glycosylation (Figure 10c). 
Gan et al. (Gan et al, 2007) reported that upon treatment with a TKI targeting 
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EGFR (AG1478) the post-translational glycosylation of the EGFR is disrupted 
leading to trafficking of immature, high mannose forms of EGFR to the cell 
surface where it contributes to increased mAb 806 binding and may increase 
ADCC activity (reviewed in Tebbutt et al, 2013).  
2) Targeting more than one receptor by dual mAbs that will prevent 
heterodimerization. For example, bi-specific monoclonal antibody, MM-111 was 
designed to target cancer cells with acquired resistance to anti-ErbB2 therapy. 
MM-111 binds to both ErbB2 and ErbB3, and form inactive trimmers and inhibits 
in vitro HRG-induced phosphorylation and cell proliferation. However, as a 
single agent MM-111 is unable to fully block ErbB2-ErbB3 heterodimerization 
(Aurisicchio et al, 2012). On the other hand MM-111 seemed to increase 
efficiency of trastuzumab and lapatinib (McDonagh et al, 2012). It has been 
shown recently that trastuzumab in combination with lapatinib (also illustrated in 
Figure 10b) inhibited in vitro and xenograft growth of human breast cancer cell 
lines significantly more than either agent alone (reviewed in Tebbutt et al, 2013). 
Likewise, the combination of cetuximab and gefitinib was shown to have 
synergistic in vitro anti-proliferative activity against the A431 cancer cell line 
(Bos et al, 1997).  
3) The use of mAbs in combination with TKIs, that will increase surface receptor 
and engage ADCC (Cavazzoni et al, 2012) (and described earlier and illustrated 
in Figure 10d), which is probably the most important clinical activity (reviewed in 
Tebbutt et al, 2013). 
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Figure 10. Enhanced anti-tumor mechanisms mediated by dual EGFR therapy. (a) 
Decreased signal intensity. The combination of an EGFR-targeted antibody with the TKI 
inhibits EGFR activation by preventing ligand binding and EGFR dimerization. This is 
probably the main mechanism associated with the use of dual therapeutics. (b) Decreased 
receptor heterodimerization. Upon heterodimerization of EGFR and ErbB2, intensity and 
diversity of signalling increases when compared with that from EGFR homodimers. The 
addition of a TKI specific for either receptor reduces signalling from the heterodimer but 
does not directly prevent dimerization. Adding an EGFR-targeted or ErbB2-targeted 
antibody in combination with the TKI directly reduces heterodimerization and prevents 
downstream signalling. (c) Induction of a conformational change in the receptor. EGFR-
specific TKIs can change the conformation of EGFR (shown as dark yellow ovals), 
increasing the binding of certain EGFR-targeted antibodies and thereby making them more 
efficient at inhibiting the receptor. (d) Induction of antibody-dependent cell cytotoxicity 
(ADCC). TKIs directed towards EGFR cause retention of the receptor on the cell surface, 
resulting in increased levels of cell-surface EGFR-targeted antibody leading to interaction 
and activation of natural killer cells more efficiently, stimulating a stronger ADCC response 
to the cancer cell. Thick black arrows indicate strong signalling, thin grey arrows indicate 
weak signalling, inhibiting arrows indicate no signalling and dashed arrows indicate 
multiple steps. Abbreviations: JAK, Janus kinase; STAT, signal transducer and activator of 
transcription. Adapted by permission from Nature Publishing Group: Nature Reviews 
Cancer (Tebbutt et al, 2013). Figure legend is modified. 
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Aims of the Study 
The overall aim of this thesis was to investigate and elaborate upon our understanding 
of the molecular mechanisms underlying endocytic downregulation of the ErbB 
proteins. A specific focus of the work was directed towards the involvement of cargo- 
specific adaptors in CME of ErbB3, the effects of ErbB2 on downregulation of 
ErbB3 and the effects of mAbs on endocytic downregulation of ErbB2. These 
research strands were intended to contribute to an overall better understanding of the 
regulatory mechanisms underpinning constitutive, ligand- or antibody-induced 
internalization of ErbB2 and ErbB3.  
 
Paper I 
The ErbB proteins are attractive targets in the development of drugs that can 
specifically interfere with molecules involved in tumorgenesis. mAbs that bind to the 
extracellular domain of the ErbB proteins have been shown to block ligand binding, 
receptor dimerization and activation as well as induce receptor downregulation. 
ErbB2 is considered endocytosis resistant and is the preferred dimerization partner 
for other ErbB family members. In our previous study we have shown that 
overexpression of ErbB2 and heterodimerization with EGFR inhibited EGF-induced 
internalization of EGFR causing a prolonged signaling. However, upon incubation 
with pertuzumab heterodimerization was inhibited and the EGF-induced 
downregulation of EGFR was enhanced (Hughes et al, 2009). The aim of the study 
presented in paper I was to investigate to what extent ErbB2 also inhibits endocytosis 
and downregulation of ErbB3, and whether pertuzumab has an effect on constitutive 
or ligand-induced signaling and downregulation of ErbB3 in cells with high levels of 
ErbB2. 
 
Paper II 
Internalization of ErbB proteins constitutes an important mechanism in shutting- 
down the signaling from activated receptors. We have previously shown that ErbB3 
is internalized constitutively in a clathrin-dependent manner (Sak et al, 2012). ErbB3 
does, however, not bind to AP-2 and in the study presented in paper II the aim was to 
identify other CLASPs which may be involved in recruiting ErbB3 into CCPs. 
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Paper III 
It has been demonstrated that most mAbs have limited in vivo anti-tumor effects 
when administrated alone. The combination of two or more antibodies does however, 
often induce downregulation of the ErbB proteins. Still, little is known about the 
molecular mechanisms causing and regulating antibody-induced internalization 
and/or degradation of ErbB proteins. The aim of the study presented in paper III was 
to investigate the ability of a mixture of two mAbs to induce ErbB2 internalization 
and degradation. We examined the involvement of clathrin-dependent and clathrin-
independent pathways, as well as the role of antibody-induced phosphorylation and 
ubiquitination in endocytic downregulation of ErbB2. 
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Summary of Papers 
Paper I 
Sak, M.M., Szymanska, M., Bertelsen, V., Hasmann, M., Madshus, I.H.  
and Stang, E.  
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of 
ErbB3.  
Carcinogenesis, 34, 2031-8, May 2013 
 
Overexpression of ErbB2 contributes to its tumor-promoting functions and is 
associated with poor patient prognosis. ErbB2 is thought to be endocytosis resistant 
and thus concentrated at the plasma membrane and is a preferred dimerization partner 
for other ErbB proteins, causing constitutive signaling and promoting cell growth and 
anti-apoptotic effects. Of special interest are ErbB2-ErbB3 heterodimers, which 
constitute the most potent oncogenic unit. In this study we investigated the effect of 
ErbB2 expression on ErbB3 downregulation and signaling, upon stimulation with or 
without the ErbB3 ligands HRG-β1 and HRG-β1 ECD and assessed for the effects of 
the anti-ErbB2 antibody pertuzumab in cell lines co-expressing ErbB3 with different 
amounts of ErbB2. We found efficient phosphorylation of and signaling from ErbB3 
only in cell lines co-expressing ErbB2, supporting the notion that efficient activation 
of ErbB3 depends on heterodimerization. Our flow cytometry data and confocal 
image analyses showed that overexpression of ErbB2, in the absence of ligand, did 
not inhibit ErbB3 internalization. We further investigated the degradation of ErbB3 in 
cell lines which co-express different levels of ErbB2. Our data indicate that 
incubation with HRG leads to heterodimerization of ErbB2 and ErbB3, which in turn 
prevents endocytosis and degradation of ErbB3. We next characterized the effects of 
pertuzumab on ligand-induced ErbB3 phosphorylation and degradation in cell lines 
co-expressing ErbB2. Our data strongly suggest that upon incubation with 
pertuzumab ligand-induced formation of ErbB2-ErbB3 heterodimers is inhibited, thus 
allowing efficient degradation of ligand-bound ErbB3 also in cell lines 
overexpressing ErbB2.  
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Paper II 
Szymanska, M., Fosdahl, A.M., Raiborg, C., Dietrich, M., Liestøl, K., Stang, E.  
and Bertelsen, V.  
Interaction with epsin 1 regulates the constitutive clathrin-dependent 
internalization of ErbB3.  
 
Manuscript 
 
ErbB3 has been demonstrated to be constitutively internalized in a clathrin-dependent 
manner, but it has also been shown that it doesn’t interact with AP-2, the main 
adaptor complex localized to the CCPs. However other CLASPs can also recruit 
cargo to the coated-pits, and in this study we performed a high-throughput siRNA 
screen to identify adaptor proteins required for constitutive internalization of ErbB3. 
We knocked down 25 CLASPs know to participate in CME as well as components of 
the AP-2 complex. CHC and dynamin 2 served as strong and milder positive controls, 
respectively, to help to identify a broad spectrum of hits. We employed an automatic 
fluorescent microscope and identified several proteins that, upon knock-down, 
interfered with the extent of ErbB3 internalization. We found that knock-down of 
epsin 1 inhibited the level of ErbB3 internalization to the same level as knock-down 
of CHC. We further confirmed that ErbB3 is constitutively ubiquitinated and that the 
ubiquitination increases upon ligand binding. Our co-immunoprecipitation data 
further showed that ErbB3 interacted with an epsin 1 mutant containing membrane 
and ubiquitin binding domains only. Thus, our data suggest that ErbB3 can interact 
with epsin 1 in an ubiquitination dependent manner and that both constitutive and 
ligand-induced CME of ErbB3 is regulated through interaction with epsin 1. 
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Paper III 
Szymanska, M., Fosdahl, A.M., Nikolaysen, F., Pedersen, M.W., Grandal, M.M., 
Stang, E. and Bertelsen V. 
 
The combination of two antibodies recognizing non-overlapping epitopes of 
ErbB2 induces ErbB2 ubiquitination and internalization in an ErbB2 kinase 
activity dependent manner.  
 
Manuscript 
 
Although ErbB2 is mainly localized to the plasma membrane, there are several ways 
to downregulate it, for example by the use of Hsp90 inhibitors or by exposure to 
mAbs, which can induce internalization and degradation of ErbB2. In this study we 
have investigated the mechanism of action of two mAbs binding to ErbB2 and 
assessed for their ability to induce downregulation of ErbB2 in cell lines 
overexpressing the receptor. We show by confocal microscopy that the mAb mixture 
induced internalization of ErbB2 and its localization to EEs and to LEs/lysosomes. 
Additionally, we demonstrate that the mAb mixture caused degradation of ErbB2. 
Furthermore, we investigated the molecular mechanisms causing downregulation of 
ErbB2 and showed that the mAb mixture induced ErbB2 phosphorylation and 
ubiquitination. Moreover, we demonstrated that inhibition of the ErbB2 kinase 
activity by lapatinib reduced antibody-induced ubiquitination, internalization and 
degradation of ErbB2. We also studied the endocytic pathways that are involved in 
antibody-induced internalization of ErbB2 and concluded that the mAb mixture 
promotes internalization of ErbB2 in a dynamin 2 and actin-dependent manner. 
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Methodological Considerations 
Cell lines 
Biological experiments are most often performed with cultured, immortalized cell 
lines because they are readily available and provide large variation in type and 
expression levels of different proteins. Cell lines are accessible for manipulation with 
gene silencing, protein overexpression and various inhibitors and therapeutics. 
However there are several disadvantages to the use of cell lines e.g. they have 
adapted to growth in culture where they are prone to genotypic and phenotypic 
changes as well as to mycoplasma infections. Therefore, we have routinely performed 
analysis for mycoplasma infections and kept all cell lines in culture for limited 
number of passages. For the current study, we have selected human cancer cell lines 
that express various levels of ErbB proteins and porcine aortic endothelial (PAE) 
cells. PAE cells, which do not express ErbB proteins endogenously (Malassagne et al, 
1998), were stably transfected with plasmids encoding different ErbB proteins alone 
or in various combinations.  
The focus of paper I was to study how ErbB2-ErbB3 heterodimerization affects 
trafficking of ErbB3 and how pertuzumab affects heterodimerization and degradation 
of ErbB3 in PAE cells expressing ErbB2 and ErbB3. In addition, we have 
investigated the ligand-induced phosphorylation of ErbB3 and activation of 
downstream signaling in PAE cell lines expressing ErbB3 only or in combination 
with either EGFR or ErbB2. PAE cell lines constitute a very useful tool to study the 
molecular mechanisms underlying receptor internalization and signalling. PAE cells 
are easy to transfect with siRNA and plasmids and, due to their flat morphology, 
make a good model for microscopy based studies. PAE cells do however, constitute a 
rather artificial system, since they do not express the ErbB proteins endogenously and 
are transfected to express receptors originating from a different species. PAE cells 
expressing EGFR only (PAE.EGFR) have been characterized before (Carter & 
Sorkin, 1998). Different PAE cell lines: PAE.EGFR.ErbB3, PAE.ErbB2.ErbB3 
(Haslekas et al, 2005; Pedersen et al, 2009), PAE.ErbB3 (Sak et al, 2012) have been 
validated and extensively used in our current and previous work. To confirm our 
findings observed in PAE cells, we have also used human breast cancer cell lines: 
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MCF-7 and SK-BR-3, which express comparable amounts of ErbB3 but varying 
levels of ErbB2.  
In paper II we have used MCF-7, a breast adenocarcinoma cell line expressing 
moderate levels of ErbB3 and very low levels of ErbB2 and EGFR. This allowed us 
to study ligand-independent internalization of ErbB3 without the influence of 
overexpression of other ErbB proteins. We also made use of HeLa cells, which have 
been extensively used in similar studies, especially regarding EGFR. HeLa cells do 
not express ErbB3 at detectable levels, but the ease of co-transfecting HeLa cells 
made it possible to study of protein- protein interactions between ErbB3 and epsin 1, 
which were not possible to achieve in MCF-7 due to the combination of low levels of 
endogenous ErbB3 and transient interaction between ErbB3 and epsin 1. 
In paper III we have used OE-19, a human oesophageal carcinoma that contains a 
100-fold ErbB2 gene amplification (Dahlberg et al, 2004). This cell line facilitated 
the study of the effects of novel therapeutic antibodies in ErbB2-dependent cancer 
cell lines. This is very important factor in our studies, since it appears that a subset of 
breast and gastric cancers with ErbB2 amplification become resistant to the existing 
treatment.  In addition, (papers I and III) we have used other cell lines overexpressing 
ErbB2, such as SK-BR-3 cells (mammary gland/ breast adenocarcinoma), and NCI-
N87 cell line (gastric carcinoma), which also express moderate levels of ErbB3 and 
EGFR. 
Chemical inhibitors 
The use of chemical inhibitors is a powerful tool to investigate the potential role of 
certain proteins in cellular processes but also has many disadvantages. In this work 
different, chemical inhibitors have been used to study internalization pathways, for 
example monensin, amiloride and cytochalasin D (paper II). In order to check the 
effect the various drugs had on clathrin-mediated endocytosis, we carried out a dose-
response assay measuring internalization of radioactive transferrin. Cytochalasin D, a 
drug that acts on actin cytoskeleton (Sampath & Pollard, 1991), primarily targeting 
phagocytosis and macropinocytosis, was used at concentrations that were reported to 
disrupt actin polymerization without causing unspecific side effects (Mortensen & 
Larsson, 2003; Stuart & Brown, 2006). Monensin, a monovalent ion-selective 
ionophore, was reported to inhibit the Na
+
/H
+
 antiporter, in consequence neutralize 
the acidic intracellular compartments such as the trans Golgi apparatus, lysosomes, 
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and certain endosomes (Mollenhauer et al, 1990). Monensin was also shown to 
inhibit exit of internalized receptors and other endocytic cargo from sorting 
endosomes and the endocytic recycling compartment (Stein et al, 1984; Tran et al, 
2003). Amiloride is reported to be a strong inhibitor of epithelial Na
+
 channel and a 
weaker inhibitor of Na
+
/H
+
 exchanger (Kleyman & Cragoe, 1988). Another inhibitor 
used in our work (paper III) is lapatinib, a potent ErbB2 and EGFR dual tyrosine 
kinase inhibitor (Xia et al, 2002). Lapatinib competes with ATP for binding to the 
kinase domain of both ErbB2 and EGFR. Titration of lapatinib was performed in 
order to determine its minimal working concentration which inhibited EGF-induced 
phosphorylation of EGFR and ErbB2. 
Transient transfections 
Transient transfection with plasmids is a method of introducing foreign genes or 
genes that are otherwise expressed only in small amounts, or mutated versions of a 
gene of interest, without incorporation into the genome. The transfection is transient 
not only because the genes are not incorporated into the genome, but because genetic 
material, i.e. the plasmid, can be lost during cell division and under the influence of 
environmental factors. This method enables the study of interaction between proteins 
that are not otherwise expressed in a particular cell line, or where endogenous levels 
are so low that it is impossible to detect it or efficiently precipitate the interacting 
complexes with the available antibodies. By transfection of different mutants that will 
compete with endogenous proteins it is possible to study specific cellular processes. 
The use of deletion mutants also allows studying functions of a particular protein 
domains. Moreover, this method allows the use of tagged proteins, which are easier 
to precipitate due to more efficient and more specific antibodies. Because it was not 
possible to co-precipitate endogenous ErbB3 and epsin 1 in MCF-7, we co-
transfected HeLa cells with two plasmids simultaneously to raise the levels of both 
proteins (paper II). We used plasmids encoding EGFP tagged deletion mutant of 
epsin 1 and wild-type ErbB3, for their better co-precipitation and detection under 
microscope. However, there are some limitations of this method i.e. some cells will 
overexpress the encoded protein to an extent that can change its normal localization 
in the cell, alter trafficking and cause unwanted protein aggregation. Conversely, not 
all cells will be transfected with the desired DNA. In the case of double transfections                                         
and single-transfected cells can be easily distinguished and immediately compared 
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when visualized under the microscope. We have used the low transfection efficiency 
to our benefit when studying the effects of EGFP- tagged dominant-                                           
negative mutant of dynamin 2 on antibody-induced internalization of ErbB2 (paper 
III) and when analyzing the effects of EGFP-ENTH-UIM epsin 1 on ErbB3 
internalization (paper II). When analyzing the cells under the confocal microscope we 
could then easily identify and distinguish transfected from non-transfected cells and                                                             
compare the cells directly in one image.  
RNA Interference 
RNA interference (RNAi), discovered by Fire and Mello (Fire et al, 1998), is post-
transcriptional processes of mRNA degradation used by different organisms to 
control protein expression. The most common way to inhibit protein expression is the 
introduction of small interfering RNA (siRNA). siRNA is a synthetic oligonucleotide 
duplex composed of 19 complementary base pairs and 2-nucleotide 3′ overhangs. 
When siRNA is introduced into a cell, it is first unwound into two single-stranded 
RNAs, the guide strand which binds to RNA-induced silencing complex (RISC) and 
the passenger strand which is degraded. Next, RISC is directed to the specific mRNA 
and, by complementary base- pairing of the guide strand with the sequence in a 
mRNA molecule, induces cleavage by argonaute, the catalytic component of the 
RISC complex. The effects of the siRNAs are transient, especially in actively 
dividing cells. While siRNA provides the opportunity to inhibit the expression of 
specific protein in a variety of cell lines, its utility is limited to cells that are simple to 
transfect. In our screen (paper II) we have tested different human cell lines for ease of 
transfection with different siRNAs and different lipid reagents and assessed for the 
specificity in protein knock-down in addition to cell viability and cytotoxicity. One of 
the disadvantages of RNAi methodology are off-target effects, which occur when an 
siRNA sequence is not specific for the protein of interest and consequently it can 
bind to, and reduce levels of, many other unwanted mRNAs. In our study we have 
used 4 individual sequences for each protein and 4 individual non-targeting (random 
sequence, not present in target genome) siRNA sequences together with siRNA to 
housekeeping genes as negative controls to ensure that the observed effects are due to 
the knock-down of the particular protein. While optimizing the assay we have also 
tested different concentrations of siRNA to find the lowest effective concentration 
such that the risk of targeting unwanted mRNAs was minimized. It is worth noting 
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that mammalian cells, as a protective mechanism, will actively respond to the 
introduction of double-stranded RNA by triggering the interferon response pathway, 
which in turn can cause off-target effects. The motifs of some siRNAs that stimulate 
interferon have not yet been identified, so caution should be exercised when 
interpreting results. RNAi is considered to be a powerful tool in recent biological 
research for the study of gene functions and also as a novel strategy in therapies. 
High-throughput screening (HTS) 
Due to its selectivity in silencing protein expression and robustness, RNAi 
technology is currently used in small and large-scale screens that systematically shut 
down the protein of interest and identify the role of specific proteins in particular 
cellular processes. RNAi has been adopted for functional genomics, endocytic 
pathway analysis, and drug target validation experiments and is now being used in 
high-throughput experiments with large numbers of siRNAs. Because of the benefits 
of HTS, which include its simplicity, rapidity, low cost, and high efficiency, we have 
implemented this technology in assessing the cellular response to siRNA knock-
down. In paper II we used siRNA to knock-down 31 selected proteins involved in 
CME and checked the effect on internalization of ErbB3. Upon knock-down of the 
selected protein, an antibody to extracellular part of ErbB3 was bound on ice and 
subsequently “chased” at 37°C. The localization of the anti-ErbB3 antibody was 
detected using secondary antibodies conjugated to the fluorescent dye. Nuclei stained 
with Hoechst were used for the automatic cell recognition and automatic image 
acquisition and assessment of the cells phenotype were used to identify statistically 
significant 'hits'. To prevent false positives and ensure the overall reliability of 
results, we have implemented appropriate statistical procedures, which took all the 
small variations in the fixation and staining protocol, as well as phenotypic variability 
between plates, into consideration. Using this approach, we were able to identify 
cargo specific adaptors involved in clathrin-mediated internalization of ErbB3. 
Wide-field fluorescent microscopy and confocal microscopy 
Wide-field fluorescence microscopy is a frequently used fluorescence imaging 
technique that relies on the simultaneous illumination of the whole sample. In paper 
II we have used an automatic wide-field fluorescent microscope to collect data from 
the thousands of cells. In this simplified approach, cells were detected based on 
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nuclei staining while internalized ErbB3 “spots” were automatically assigned to a 
particular cell and their number and intensity were counted. One of the biggest 
challenges encountered while using automatic microscope was to ensure that the 
surface in each well of a 96-well plate was covered with a uniform, flat layer of 
adherent cells. During scanning of the plate by the microscope, the objective was 
moving from one well to another and for each image the focus had to be set on given 
objects, in this instance the cell nuclei. Whenever there was an empty spot in a well, 
focus was lost and the recorded images were of poor quality, making it impossible to 
analyze the cells. Therefore, we took a great care to ensure that confluence of the 
cells on the day of image acquisition is in not less that 60% and not more than 90%. 
Confocal microscopy enables visualization within both living and fixed cells and 
tissues with increased optical resolution and contrast. Confocal microscopy takes 
advantage of the spatial pinhole and point illuminations to eliminate out-of-focus 
light and increase resolution in x and y planes. In papers I and III we have primarily 
used confocal microscope to analyze in more detail the nature of intracellular 
structures, especially when studying the colocalization of the receptors with markers 
of early or late endosomes. For each experiment many cells were analyzed to correct 
for individual cell variations and each experiment was performed minimum three 
times to account for technical variations in the staining protocol. A number of 
important points must be kept in mind when working with confocal microscopes and 
caution should be taken when interpreting the results. All merged images must be 
taken in the same z-plane. Sometimes plasma membrane proteins may appear to 
colocalize with markers of intracellular compartments especially when the protein is 
overexpressed and generates a strong fluorescent signal. In this case a good solution 
could be to use so called superresolution microscopes, such as STED (stimulated 
emission depletion), STORM (stochastic optical reconstruction microscopy) or 
electron microscope. When using combinations of secondary antibodies conjugated 
to different dyes, a bleed-through caused by overlapping excitation or/and emission 
light can occur, which in turn can lead to misinterpretation of the data. To minimize 
this problem we have taken images of different fluorochromes sequentially, where 
the dye with the longest emissions was scanned first and the dye with the shortest 
emissions was scanned last. To avoid masking the specimen signal and to avoid the 
false-positive signal we have quenched, with ammonium chloride, autofluorescent 
signal arising from aldehyde groups present in the fixative. Finally, all presented 
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images were taken below saturation level for each fluorochrome and processed with 
Adobe Photoshop or Image J to adjust brightness and contrast. 
Immunological detection 
Immunological detection is based on antigen epitope- antibody interaction and it 
depends on antibody specificity and the state of the protein (native/denaturated) as 
well as on antibody concentration, incubation time and temperature. The protein of 
interest is detected due to binding of the antigen specific “primary” antibody, which, 
in the next step, is detected by the specific “secondary” antibody. To facilitate 
visualization of the protein, enzymes or fluorescent dyes can be bound to the 
secondary antibodies (indirect detection), as well as to primary antibodies (direct 
detection). The direct detection method has a few advantages such as the reduced 
number of steps in the staining protocol and avoidance of antibody cross-reactivity or 
non-specificity, but also is less sensitive in terms of signal amplification. By using an 
indirect detection method, signal amplification can be increased because several 
secondary antibodies may bind to a single primary molecule. The biggest challenge 
when working with immuno-based detection methods is to use primary antibodies 
that are specific for protein of interest (discussed in the below paragraphs).  
Detection of the ErbB proteins, their localization and interaction with other proteins 
was based on an indirect method utilizing fluorescent dyes conjugated to the 
secondary antibodies. To study the localization of two (or three) proteins in the same 
cell by confocal microscopy, double (or triple) staining was applied. When 
combining two or more primary antibodies in one setup, we used antibodies from 
different species. To make sure that there was no cross-reaction between multiple 
antibodies, a control tests lacking one of the primary antibody or using the primary 
antibody raised in different species than the secondary antibody, were always 
performed at the beginning of each new experiment. Also, when performing double 
(and triple) staining it is important to use secondary antibodies conjugated to 
varicolored dyes, which emission lights do not overlap. 
Another application of the antibody-based detection method used most frequently in 
this work is western blot. Western blot is a technique designed to detect proteins 
present in lysates from different cells and tissues. Proteins in the lysates are 
denaturated and separated by SDS-PAGE (sodium dodecyl sulfate-polyacrylaminde 
gel electrophoresis) according to their size. Next, proteins are transferred to a 
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membrane, typically nitrocellulose or PVDF, where they are detected by specific 
antibodies. The specificity of the antibodies in recognizing different ErbB proteins 
was tested in PAE cell lines that express only one member of the ErbB family. To 
this end, a novel system for gel electrophoresis was applied, Mini-PROTEAN TGX 
Precast Gels from Bio-Rad™. This innovative method enabled faster protein 
separation and transfer to a nitrocellulose membrane, which was usually 
accomplished in less than 1 h. Proteins were detected by the use of secondary 
antibodies conjugated to horseradish peroxidase (HRP), which produced 
chemiluminescence that was recorded by camera. Images, which were acquired 
below saturation level, were processed by Image Lab 4.1 software (Bio-Rad) and 
subjected to quantification based on pixel intensity. To account for variations 
between samples, all the values were normalized to the protein- loading control that 
was run on the same gel in parallel with the protein of interest. In should be 
mentioned that densitometric analysis can be inaccurate, as it may be affected by the 
size and intensity of the band and background noise. Therefore, the western blot 
image that was quantified was always presented along with the quantification. 
Studies of protein-protein interaction by IP and Co-IP 
When analyzing particular protein-protein interactions it is important to make sure 
that all non-interacting proteins will be excluded from the sample. Isolation of 
proteins of interest can be achieved by immunoprecipitation (IP) and co-IP. In papers 
II and III, to properly precipitate proteins from the cell lysates, antibodies recognizing 
the protein of interest were pre-bound to magnetic beads coupled with Protein A or 
Protein G. Next, precipitates were eluted in the SDS-buffer to ensure the proper 
denaturation of proteins as well as antibodies which will dissociate from the beads 
and can be analyzed by western blotting. In a control sample, beads without pre-
bound antibodies were incubated with the cell lysates, to control for unspecific 
interaction between beads and proteins present in the cell lysates. When analyzing 
ubiquitination of ErbB3 (paper II) and ErbB2 (paper III) cells were subjected to hot 
(96˚C) SDS-based lysis, which caused protein denaturation but did not destroy 
covalent bonds between ubiquitin molecules and receptor. When analyzing 
interaction of ErbB3 and epsin 1, co-IP method was used. In this case, cells were 
handled with precaution and lysis was performed, in a buffer without strong 
denaturating agents and with addition of phosphates and protease inhibitors to avoid 
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dissociation of protein complexes. To ensure that active enzymes did not cause 
denaturation and degradation of proteins, cells and cell lysates were kept on ice and 
always washed in buffers containing inhibitor cocktails.  
Internalization of radioactive transferrin (125I-Tf) 
Transferrin is internalized in clathrin-dependent manner only. Internalization of 
radioactive labeled Tf was used as a quantitative assay to confirm the specificity of 
siRNA silencing of the major components of the clathrin-mediated endocytosis and 
chemical inhibition of CIE. Internalization of radioactive labeled Tf  constitutes very 
sensitive and quantitative method of detection of even small amounts of 
intracellularly localized ligand. However, one needs to remember to handle the 
radioactive solutions and hazardous waste with precaution. 
Immuno-electron microscopy 
In paper III we have employed immuno-electron microscopy (immuno-EM) to study 
antibody- induced internalization of ErbB2 in more detail. Immuno-EM offers several 
advantages over light-based microscopy, having higher resolution than confocal 
microscope and allowing electron dense protein coats at the plasma membrane and 
internal vesicles of multivesicular bodies to be detected without using specific 
markers. As for other antibody based techniques, immuno-EM is depending on 
antibody specificity and labeling efficiency. Since the labeling efficiency differs for 
each antibody and each antigen, and also depends on the size of the colloidal gold 
used for labeling, a direct comparison of labeling intensities is not possible.  
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General Discussion 
The oncogenic potency of the ErbB2-ErbB3 heterodimer has recently gained an 
increased interest due to several findings showing that ErbB3, in addition to mediate 
anti-apoptotic signaling, is responsible for acquired resistance to anti-EGFR and anti-
ErbB2 therapies (reviewed in Telesco et al, 2011). Upregulation of ErbB3 is 
commonly seen in various malignancies, such as colorectal carcinoma, gastric, 
ovarian, prostate, bladder and breast cancers. In some human breast cancers ErbB3 is 
upregulated, both at mRNA and protein levels, and this seems to be associated with 
metastasis, tumor size, and risk of local recurrence (Huotari & Helenius, 2011). 
Furthermore, Begnami et al., found that, in gastric carcinomas, ErbB3 was the most 
common partner for dimerization, especially with ErbB2, and both receptors were 
shown to be the significant predictors of poor survival (Begnami et al, 2011). 
Therefore, studies investigating molecular factors regulating dimerization and 
downregulation of ErbB2 and ErbB3, which in turn will help to understand 
mechanisms of drug-resistance and develop new or improve existing targeted 
therapeutics, are of great importance. Previous studies from our group (Sak et al, 
2012) demonstrated that ErbB3 is constitutively internalized through CME, and our 
current study (paper II) shows that epsin 1 plays a crucial role as cargo-specific 
adaptor for ErbB3. The study also demonstrated that ErbB3 is constitutively 
ubiquitinated and that the ubiquitination is enhanced in the presence of ligand, which 
is in agreement with other studies showing that ubiquitination regulates plasma 
membrane expression of ErbB3 both in the presence or absence of the ligand (Cao et 
al, 2007; Diamonti et al, 2002; Huang et al, 2015). Our data show an interaction 
between ErbB3 and an epsin 1 mutant containing its UIMs, but lacking its clathrin 
and AP-2 binding regions, furthermore suggests that epsin 1 regulates ErbB3 by 
recruiting ubiquitinated ErbB3 into coated pits. Such a mechanism has not previously 
been shown for ErbB3, but is in line with our previous studies on epsin 1 as adaptor 
in CME of ubiquitinated EGFR and ErbB2 (Bertelsen et al, 2011; Kazazic et al, 
2009; Vuong et al, 2013). Our group has ongoing investigations focusing on 
unraveling the mechanisms for endosomal sorting and degradation of ErbB3. In the 
future it will be interesting to explore the role of intracellular localized ErbB3, 
especially with respect to existence and duration of ErbB3-mediated signaling.  
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ErbB3 has been considered to be kinase-inactive but in line with previous finding 
(Shi et al, 2010) we report that in fact ErbB3 has a weak kinase activity and is able to 
form homodimers. However, we also show that co-expression of ErbB3 along with 
ErbB2, clearly increased ligand-induced activation of ErbB3 and downstream 
signaling, supporting that ErbB3 heterodimerization is important for efficient signal 
transduction. 
In order to inhibit the activity of ErbB proteins, highly specific and fully inactivating 
therapeutics have to be used (Tebbutt et al, 2013). One strategy involves the use of 
mAbs that target ErbB proteins and can prevent ligand binding and/or receptor 
dimerization and/or decrease surface expression of the targeted receptor. We have 
previously demonstrated that pertuzumab counteracted the inhibitory effect of ErbB2 
on EGF-induced degradation of the EGFR in cells overexpressing ErbB2 (Hughes et 
al, 2009). Pertuzumab was also reported to inhibit HRG-dependent morphogenesis in 
vitro and to induce tumor regression in ligand-dependent breast cancer xenograft 
model (Lee-Hoeflich et al, 2008). In paper I we show that upon incubation with 
pertuzumab HRG-induced phosphorylation of ErbB3 and downstream signaling were 
reduced, which supports the notion that pertuzumab inhibits ligand-induced ErbB2-
ErbB3 heterodimerization. Pertuzumab inhibited ligand-induced downstream 
signaling even in cell lines expressing low levels of ErbB2. Thus, our findings 
indicate that the use of pertuzumab can be beneficial also in treatment of cancer 
patients with ErbB3 positive tumors showing low ErbB2 expression.  
The molecular mechanisms of action of therapeutic antibodies are complex and not 
fully understood. Clinical activity of single antibodies, such as pertuzumab and 
trastuzumab is limited but when these two agents were combined they showed 
synergistic anti-tumor effects (Gianni et al, 2012). In preclinical studies single mAbs 
were reported to induce internalization of ErbB2 (Klapper et al, 2000), but several 
other studies have demonstrated that a mixture of two or three mAbs is much more 
effective in downregulation of ErbB2 (Ben-Kasus et al, 2009; Friedman et al, 2005; 
Pedersen et al, 2015). In line with this, we detected (paper III) efficient 
downregulation of ErbB2 upon treatment with the mAb mixture but not upon single 
mAbs. Whether mAbs induce internalization or inhibit recycling of the targeted 
receptors is still debated. Our data support the notion that incubation with the mAb 
mixture caused internalization of ErbB2, since treatment with monensin, a recycling 
inhibitor, resulted in only minimal intracellular localization of ErbB2, while 
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treatment with mAb mixture had much more pronounced effects. In addition we show 
that the mAb mixture induced efficient ubiquitination of ErbB2. While ubiquitination 
of ErbB2 upon Hsp90 inhibitors is reported to be a result of recruitment of Hsp70 
along with ubiquitin ligases, a different mechanism seems to be responsible for the 
antibody-induced ErbB2 ubiquitination since we found no recruitment of Hsp70 to 
ErbB2 upon incubation with the antibodies. With respect to internalization of EGFR, 
Cbl-induced ubiquitination was shown to recruit EGFR into CCPs (Bertelsen et al, 
2011; Stang et al, 2004). Recruitment of Cbl to phosphorylated Tyr1045 of EGFR 
can be either direct or indirect, via Grb2 (Huang & Sorkin, 2005; Sorkin & Goh, 
2008). In our current study we show that upon incubation with the mAb mixture, 
ErbB2 becomes efficiently phosphorylated in general and specifically to some degree 
at Tyr1112 of ErbB2. This site, which corresponds to Tyr1045 in EGFR, has 
previously been shown to be a binding site for c-Cbl (Klapper et al, 2000). However, 
since we do not get any inhibitory effect upon knock down of c-Cbl or Cbl-b our 
results indicate that antibody-induced ubiquitination of ErbB2 is not depending on 
Cbl. Hence, the ubiquitin ligase machinery accountable for the antibody-induced 
ubiquitination of ErbB2 remains to be identified.  
Ubiquitination can, among others, be a signal for endocytosis. Whether it is a signal 
for CME or CIE or both is however discussed. For ubiquitinated EGFR both 
pathways seem to be involved (Madshus & Stang, 2009; Sigismund et al, 2005; 
Sorkin & Goh, 2008). A previous study from our group did however demonstrate that 
a chimeric pre-ubiquitinated ErbB2 was internalized in a clathrin-dependent manner 
(Vuong et al, 2013). In the case of antibody-induced internalization of ErbB2 we 
found that both CME and CIE are involved. To what extent the internalization 
depends on ubiquitination is uncertain since we were not able to specifically inhibit 
ubiquitination without also inhibiting ErbB2 phosphorylation. In a previous study we 
found that the combination of antibodies forming complexes with EGFR efficiently 
downregulated the receptor primarily by induction of macropinocytosis (Berger et al, 
2012). Our current data can thus support the view that antibody-induced crosslinking 
of receptors, like ErbB2, at the plasma membrane in itself is sufficient to initiate CIE. 
The study of Orth et al. (Orth et al, 2006) demonstrated that a large portion of 
activated EGFR can be internalized from the plasma membrane through circular 
dorsal ruffles. This pathway requires EGFR kinase activity, and it depends on PI3K, 
actin and dynamin 2. Moreover, they show that this pathway occurs independently 
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and in parallel to CME, which is in agreement with our observations that both CME 
and CIE are involved in antibody-induced internalization of ErbB2 and that dynamin 
2- and actin-dependent CIE appears to be the major pathway. 
Another strategy of targeting ErbB proteins in therapy involves the use of TKIs. 
Interestingly, we found that upon inhibiting ErbB2 kinase activity, the antibody-
induced internalization and degradation of ErbB2 were inhibited. Thus, our results 
imply that kinase activity is a required step for antibody-induced downregulation of 
ErbB2. However, we do not know whether ErbB2 kinase activity is needed for 
recruitment of ubiquitin ligases or for downstream activation of PI3K and 
accumulation of its major lipid product, PIP3 leading to e.g. actin rearrangement 
facilitating CIE uptake of antibody-ErbB2 complexes. 
From a therapeutic point of view the different effects of mAbs alone compared to 
mAbs in combination with TKIs are interesting. One may speculate that on one hand, 
treatment with mAbs alone will reduce cell surface levels of targeted receptor leading 
to decreased oncogenic signaling. On the other hand, a TKI induced increase of 
inactive ErbB2 at the plasma membrane would enhance binding of the therapeutic 
antibodies and thus induce stronger ADCC. Based on this our current results indicate 
that TKIs may enhance the therapeutic effects of mAbs (also discussed in Scaltriti et 
al, 2009) however, further studies on synergistic effect of mAbs and TKIs are 
required.  
Overall, by employing basic science, this work gives insight into the molecular 
mechanism involved in regulation of ErbB2 and ErbB3, two oncoproteins that are 
very important targets in rational design of anti-cancer therapeutics. 
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